

min D₃]: ¹H NMR (CDCl₃) δ 0.64 (3 H, s, H-18), 0.87 (3 H, t, J = 7.2 Hz, (CH₂)₃CH₃), 0.94 (3 H, d, J = 6.4 Hz, H-21), 1.22 (6 H, s, H-26,27), 4.07 (2 H, m, H-1,3), 6.12 (1 H, d, J = 11.5 Hz, H-7), 6.46 (1 H, d, J = 11.5 Hz, H-6). UV (EtOH) λ_{max} 244, 252, and 261 nm. MS *m/z* (%) 460 (M⁺, 18), 442 (100), 424 (33), 406 (17), 331 (36), 313 (33), 295 (22).

5-Allyl-1-(5-methoxymethoxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-one (24b). To a solution of *i*Pr₂NH (706 μL, 5.04 mmol) in THF (10 mL) at -20 °C was added *n*-BuLi (2.8 mL, 4.37 mmol, 1.58 M hexane), and the mixture was stirred for 15 min. Ketone **5** (1.09 g, 3.36 mmol) in THF (5 mL) was added to the LDA solution at -78 °C, the mixture was stirred for 1 h at that temperature, and then TMSCl (436 μL, 5.04 mmol) and Et₃N (702 μL, 5.04 mmol) were added. The temperature of the reaction was raised to -20 °C for 1.5 h. The solvent was evaporated, the residue was dissolved in hexane, and the mixture was passed through Celite to give **23** (1.34 g). To a solution of silyl enol ether **23** (1.3 g, 3.36 mmol) in THF (5 mL) at 0 °C was added a solution of MeLi (1.2 M Et₂O, 3.4 mL, 4.06 mmol), and the mixture was stirred for 1 h. This mixture was added to a solution of allyl iodide (631 μL, 6.77 mmol) in THF (2 mL) at -78 °C. The mixture was stirred for 1 h while raising the temperature to -45 °C. NH₄Cl solution was added to the reaction, and the mixture was extracted with AcOEt, the extract was washed with brine, dried over MgSO₄, and evaporated to dryness. The residue was chromatographed on silica gel (30 g) with 8–10% AcOEt/hexane to give **24b** (887.7 mg, 73%, 2 steps). **24b** ¹H NMR (CDCl₃) δ 0.66 (3 H, s, H-18), 0.96 (3 H, d, J = 6.2 Hz, H-21), 1.22 (6 H, s, H-26, 27), 2.57 (1 H, dd, J = 11.5, 7.4 Hz, H-14), 3.37 (3 H, s, OCH₃), 4.70 (2 H, s, OCH₂O), 5.09 (2 H, m, CH₂CH=CH₂), 5.68 (1 H, m, CH₂CH=CH₂). MS *m/z* (%) 364 (M⁺, 6), 323 (8), 302 (76), 261 (17), 219 (68), 191 (25), 55 (100).

5-Allyl-1-(5-methoxymethoxy-1,5-dimethyl-hexyl)-7a-methyl-4-vinyl-octahydro-inden-4-ol (25b). To a solution of **24b** (887.7 mg, 2.4 mmol) in THF (7 mL) at 0 °C was added a solution of vinyl magnesium bromide (1 M THF solution, 4.87 mL, 4.87 mmol), and the mixture was stirred for 2 h. The reaction mixture was treated as described above for the synthesis of **25a**. The residue was chromatographed on silica gel (10 g) and eluted with 10% AcOEt/hexane to give **25b** (759.1 mg, 79%). **25b**: ¹H NMR (CDCl₃) δ 0.91 (3 H, d, J = 6.5 Hz, H-21), 0.97 (3 H, s, H-18), 1.21 (6 H, s, H-26, 27), 3.37 (3 H, s, OCH₃), 4.71 (2 H, s, OCH₂O), 4.99 (2 H, m, CH₂CH=CH₂), 5.05 (1 H, dd, J = 10.8, 1.5 Hz, H-6), 5.25 (1 H, dd, J = 17.2, 1.5 Hz, H-6), 5.69 (1 H, m, CH₂CH=CH₂), 5.91 (1 H, dd, J = 17.2, 10.8 Hz, H-7). MS *m/z* (%) 392 (no M⁺), 330 (53), 312 (50), 297 (14), 271 (20), 247 (87), 219 (20), 201 (49), 55 (100).

[5-Allyl-1-(5-methoxymethoxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-acetaldehyde (26c). To a solution of **25b** (759.1 mg, 1.93 mmol) in CH₂Cl₂ (30 mL) were added PCC (1.67 g, 7.73 mmol) and Celite (1.7 g), and the mixture was stirred at room temperature for 23 h. The reaction mixture was chromatographed on silica gel (20 g) and eluted with 2% AcOEt/hexane to give aldehyde **26c** (669.3 mg, 89%). **26c**: ¹H NMR (CDCl₃) δ 0.62 (3 H, s, H-18), 0.95 (3 H, d, J = 5.7 Hz, H-21), 1.22 (6 H, s, H-26, 27), 3.37 (3 H, s, OCH₃), 3.47 (1 H, m, H-9), 4.71 (2 H, s, OCH₂O), 5.03 (2 H, m, CH₂CH=CH₂), 5.68 (1 H, m, CH₂CH=CH₂), 5.76 (1 H, dd, J = 8.3, 1.5 Hz, H-7), 10.01 (1 H, d, J = 8.2 Hz, CHO). MS *m/z* (%) 390 (M⁺, 6), 328 (71), 287 (52), 217 (28), 215 (100).

2-[5-Allyl-1-(5-methoxymethoxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethanol (26d). NaBH₄ (63.9 mg, 1.69 mmol) was added to a solution of aldehyde **26c** (660.1 mg, 1.69 mmol) in EtOH (10 mL) at 0 °C, and the mixture was stirred for 1 h. The mixture was treated as described above for the synthesis of **26b**. Chromatography of the product on silica gel (20 g) and elution with 20–25% AcOEt/hexane gave alcohol **26d** (400.6 mg, 61%). **26d**: ¹H NMR (CDCl₃) δ 0.56 (3 H, s, H-18), 0.93 (3 H, d, J = 6.4 Hz, H-21), 1.22 (6 H, s, H-26, 27), 2.73 (1 H, dd, J = 13.9, 7.1 Hz, H-9), 3.37 (3 H, s, OCH₃), 4.14 (2 H, d, J = 6.8 Hz, H-6), 4.71 (2 H, s, OCH₂O), 4.97 (2 H, m, CH₂CH=CH₂), 5.28 (1 H, dd, J = 7.1, 1.6 Hz, H-7), 5.70 (1 H, m, CH₂CH=CH₂). MS *m/z* (%) 392 (no M⁺), 330 (100),

312 (53), 299 (64), 289 (19), 271 (41), 245 (47), 219 (32), 217 (49), 201 (72).

2-[2-[5-Allyl-1-(5-methoxymethoxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethanesulfonyl]-benzothiazole (30). To a solution of alcohol **26d** (108.8 mg, 0.277 mmol) in CH₂Cl₂ (2 mL) were added Ph₃P (109 mg, 0.416 mmol), 2-mercaptobenzothiazole (69.5 mg, 0.416 mmol), and DIAD (57.4 μL, 0.277 mmol), and the mixture was stirred at 1 h. The solvent was evaporated, and the residue was dissolved in EtOH (2.5 mL) and cooled to 0 °C. To this solution were added 30% H₂O₂ (300 μL) and (NH₄)₆Mo₇O₂₄·4H₂O (68.5 mg, 0.055 mmol), and the mixture was stirred for 1 h at room temperature. The reaction was quenched with 2 N Na₂SO₃ solution, and the mixture was extracted with AcOEt. The extract was washed with brine, dried over MgSO₄, and evaporated. The residue was chromatographed on silica gel (5 g) and eluted with 7% AcOEt/hexane to give **30** (158 mg, 97%). **30**: ¹H NMR (CDCl₃) δ: 0.17 (3 H, s, H-18), 0.84 (3 H, d, J = 6.1 Hz, H-21), 1.20 (6 H, s, H-26, 27), 2.70 (1 H, m, H-9), 3.36 (3 H, s, OCH₃), 4.06 (1 H, ddd, J = 14.4, 5.9, 2.0 Hz, H-6), 4.54 (1 H, dd, J = 14.4, 9.8 Hz, H-6), 4.69 (2 H, s, OCH₂O), 4.94 (2 H, m, CH=CH₂), 5.06 (1 H, m, H-7), 5.64 (1 H, m, CH=CH₂), 7.61, 8.00, 8.21 (2 H, 1 H, 1 H, m, arom-H).

9α-Allyl-1α-(tert-butylidimethylsilyloxy)-2-[2-(tert-butylidimethylsilyloxy)-ethylidene]-25-methoxymethoxy-19-norvitamin D₃ 3-(tert-butylidimethylsilyl) Ether (32). A solution of LHMDS (1.0 M THF, 230 μL, 0.23 mmol) was added to a solution of sulphone **30** (158.0 mg, 0.269 mmol) in THF (1.5 mL) at -78 °C, the solution was stirred for 30 min, and to this solution, a solution of A-ring ketone **31** (69.3 mg, 0.155 mmol) in THF (1 mL) was added. The mixture was stirred for 1 h at -78 °C, the temperature was raised to 0 °C, and the mixture was stirred at that temperature for 1 h. Saturated NH₄Cl solution was added to the reaction, and the mixture was extracted with AcOEt. The extract was washed with brine, dried over MgSO₄, and evaporated. The residue was chromatographed on silica gel (10 g) and eluted with 3% AcOEt/hexane to give **32** (112.4 mg, 83% on the basis of recovered **30**) as a mixture of *E*- and *Z*-isomers (5:3) and with 10% AcOEt/hexane sulphone **30** (64.8 mg, 41%). **32a** (*E* isomer): ¹H NMR (CDCl₃) δ 0.05–0.09 (18 H, Si-Me × 6), 0.56 (3 H, s, H-18), 0.82–0.94 (30 H, Si-*t*Bu × 3, H-21), 1.22 (6 H, s, H-26, 27), 3.37 (3 H, s, OCH₃), 4.25–4.45 (3 H, m, H-1, CH₂OTBS), 4.71 (2 H, s, OCH₂O), 4.78 (1 H, m, H-3), 4.97 (2 H, m, CH=CH₂), 5.61 (1 H, m, C=CH), 5.72 (1 H, m, CH=CH₂), 5.89 (1 H, d, J = 11.1 Hz, H-7), 6.12 (1 H, d, J = 11.1 Hz, H-6). **32b** (*Z* isomer): ¹H NMR (CDCl₃) δ 0.05–0.09 (18 H, Si-Me × 6), 0.54 (3 H, s, H-18), 0.82–0.94 (30 H, Si-*t*Bu × 3, H-21), 1.22 (6 H, s, H-26, 27), 3.37 (3 H, s, OCH₃), 4.25–4.45 (3 H, m, H-3, CH₂OTBS), 4.71 (2 H, s, OCH₂O), 4.78 (1 H, m, H-1), 4.97 (2 H, m, CH=CH₂), 5.61 (1 H, m, C=CH), 5.72 (1 H, m, CH=CH₂), 5.83 (1 H, d, J = 10.4 Hz, H-7), 6.22 (1 H, d, J = 10.4 Hz, H-6). MS *m/z* (%) 872 (M⁺, 3), 740 (68), 678 (100), 621 (8).

9α-Allyl-1α,25-dihydroxy-2-(2-hydroxyethylidene)-19-norvitamin D₃ (4b and 4c). CSA (77 mg, 0.332 mmol) was added to a solution of **32** (48.0 mg, 55 μmol) in MeOH (1 mL), and the mixture was stirred for 1.5 h at room temperature. A 5% NaHCO₃ solution was added to the reaction, the mixture was extracted with AcOEt, and the extract was washed with brine, dried over MgSO₄, and evaporated. The residue was chromatographed on silica gel (5 g) and eluted with 2% MeOH/AcOEt to give a mixture of **4b** and **4c** (*E*- and *Z*-isomers at the position 2) (24.2 mg, 90%). The mixture was separated by HPLC [YMC-Pack ODS-AM SH-342-S, 20% H₂O/MeOH, 8 mL/min] to give **4b** (*E*-isomer) (14.15 mg, RT 34.80) and **4c** (*Z*-isomer) (8.49 mg, RT 37.10). **4b**: ¹H NMR (CDCl₃) δ: 0.55 (3 H, s, H-18), 0.94 (3 H, d, J = 6.2 Hz, H-21), 1.22 (6 H, s, H-26, 27), 2.42 (2 H, m, H-4), 2.92 (1 H, m, H-9), 3.13 (1 H, dd, J = 13.0, 4.8 Hz, H-10), 4.15 (1 H, dd, J = 12.5, 5.8 Hz, CH₂OH), 4.37 (1 H, dd, J = 12.5, 8.1 Hz, CH₂OH), 4.40 (1 H, m, H-1), 4.82 (1 H, m, H-3), 4.97 (2 H, m, CH=CH₂), 5.73 (1 H, m, CH=CH₂), 5.80 (1 H, m, C=CH), 5.90 (1 H, d, J = 11.1 Hz, H-7), 6.26 (1 H, d, J = 11.1 Hz, H-6). UV λ_{max} (EtOH) 247, 255, and 264 nm. **4c**: ¹H NMR (CDCl₃) δ 0.56 (3 H, s, H-18), 0.94 (3 H, d, J = 6.2 Hz, H-21), 1.22 (6 H, s, H-26, 27), 4.19 (1 H, dd, J = 12.5, 6.0 Hz, CH₂OH), 4.37 (1 H, dd, J = 12.5, 7.9 Hz, CH₂OH), 4.45 (1 H, m, H-3), 4.87 (1 H, m, H-1), 4.97 (2 H, m, CH=CH₂), 5.72 (1 H, m,

$\text{CH}=\text{CH}_2$), 5.81 (1 H, m, $\text{C}=\text{CH}$), 5.87 (1 H, d, $J = 11.2$ Hz, H-7), 6.37 (1 H, d, $J = 11.2$ Hz, H-6). MS m/z (%): 486 (M^+ , 17), 468 (17), 450 (30), 432 (61), 391 (100). UV λ_{max} (EtOH) 247, 255, and 264 nm.

1 α -(*tert*-Butyldimethylsilyloxy)-2-[2-(*tert*-butyldimethylsilyloxy)ethylidene]-9 α -(3-hydroxypropyl)-25-methoxymethoxy-19-norvitamin D₃ 3-(*tert*-Butyldimethylsilyl) Ether (33). To a solution of 32 (57.7 mg, 0.0661 mmol, *E:Z*, 5:3) in THF (300 μL) was added 9-borabicyclo[3.3.1]nonane (9-BBN) (1.32 mL, 0.661 mmol, 10.0 equiv) at room temperature, and the mixture was stirred for 1.5 h. MeOH (220 μL) was added to the reaction, and the mixture was stirred for 15 min. The mixture was cooled to 0 °C, and 6 M NaOH (220.2 μL , 1.32 mmol, 20.0 equiv) and 30% H₂O₂ (220 μL) were added. The mixture was stirred at room temperature for 1 h. To the reaction, 2 N HCl was added, and the mixture was extracted with AcOEt. The organic layer was washed with brine, dried over MgSO₄, and evaporated. The residue was chromatographed on silica gel (10 g) and eluted with 8% EtOAc/hexane to give 33a (2*E*-isomer, 13.1 mg, 22%) and with 10% AcOEt/hexane to give 33b (2*Z*-isomer, 11.1 mg, 19%). 33a: ¹H NMR (CDCl₃) δ 0.05–0.08 (18 H, Si-Me \times 6), 0.55 (3 H, s, H-18), 0.83, 0.89, 0.93 (each 9 H, s, Si-*t*Bu \times 3, overlapped with H-21), 1.22 (6 H, s, H-26, 27), 2.86 (1 H, m, H-9), 3.00 (1 H, dd, $J = 12.7, 4.7$ Hz, H-10), 3.37 (3 H, s, OCH₃), 3.61 (2 H, m, CH_2OH), 4.25–4.38 (3 H, m, H-1, CH_2OTBS), 4.71 (2 H, s, OCH₂O), 4.78 (1 H, m, H-3), 5.61 (1 H, m, $\text{C}=\text{CH}$), 5.93 (1 H, d, $J = 11.1$ Hz, H-7), 6.11 (1 H, d, $J = 11.1$ Hz, H-6). MS m/z (%) 890 (M^+ , 2), 828 (5), 758 (52), 696 (100), 626 (10), 75 (93). 33b: ¹H NMR (CDCl₃) δ 0.06–0.09 (18 H, Si-Me \times 6), 0.54 (3 H, s, H-18), 0.82, 0.90, 0.93 (each 9 H, s, Si-*t*Bu \times 3, overlapped with H-21), 1.22 (6 H, s, H-26, 27), 3.37 (3 H, s, OCH₃), 3.61 (2 H, m, CH_2OH), 4.30 (2 H, m, CH_2OTBS), 4.44 (1 H, m, H-3), 4.71 (2 H, s, OCH₂O), 4.83 (1 H, m, H-1), 5.61 (1 H, m, $\text{C}=\text{CH}$), 5.87 (1 H, d, $J = 10.4$ Hz, H-7), 6.22 (1 H, d, $J = 10.4$ Hz, H-6). MS m/z (%) 890 (M^+ , 1), 828 (1), 758 (20), 696 (22), 626 (4), 75 (100).

(2*E*)-1 α ,25-Dihydroxy-2-(2-hydroxyethylidene)-9 α -(3-hydroxypropyl)-19-norvitamin D₃ (4d). To a solution of 33a (13.1 mg, 0.0147 mmol) in MeOH (300 μL) was added CSA (34.1 mg, 0.147 mmol, 10.0 equiv), and the mixture was stirred for 2 h. Then, 5% NaHCO₃ was added to the reaction, the mixture was extracted with AcOEt, and the organic layer was washed with brine, dried with MgSO₄, and evaporated. The residue was chromatographed on silica gel (5 g) and eluted with 5% MeOH/AcOH to give 4d (5.7 mg, 77%). 4d: ¹H NMR (CDCl₃) δ : 0.56 (3 H, s, H-18), 0.94 (3 H, d, $J = 6.0$ Hz, H-21), 1.22 (6 H, s, H-26, 27), 2.17 (1 H, t, $J = 8.7$ Hz), 2.29, 2.41 (each 1 H, m, H-4), 2.89 (1 H, m, H-9), 3.16 (1 H, m, H-10), 3.48, 3.60 (each 1 H, m, $\text{CH}_2\text{CH}_2\text{OH}$), 4.09 (1 H, m, CH_2OH), 4.31 (3 H, m, H-1, CH_2OH , OH), 4.40 (1 H, br.s, OH), 4.80 (1 H, m, H-3), 5.74 (1 H, m, $\text{C}=\text{CH}$), 5.97 (1 H, d, $J = 10.6$ Hz, H-7), 6.11 (1 H, d, $J = 10.6$ Hz, H-6). MS m/z (%): 504 (M^+ , 1), 486 (10), 468 (34), 450 (57), 432 (24), 386 (100), 339 (14). UV λ_{max} (EtOH): 246, 254, and 264 nm.

(2*Z*)-1 α ,25-Dihydroxy-2-(2-hydroxyethylidene)-9 α -(3-hydroxypropyl)-19-norvitamin D₃ (4e). 33b (2*Z*-isomer, 11.1 mg, 0.0124 mmol) was deprotected similarly to give 4e (3.4 mg, 54%). 4e: ¹H NMR (CDCl₃) δ 0.56 (3 H, s, H-18), 0.93 (3 H, d, $J = 6.3$ Hz, H-21), 1.22 (6 H, s, H-26, 27), 2.38 (1 H, m, H-10), 2.66 (1 H, dd, $J = 13.0, 4.6$ Hz, H-4), 2.76 (1 H, dd, $J = 14.0, 5.7$ Hz, H-10), 2.89 (1 H, m, H-9), 3.61 (2 H, m, $\text{CH}_2\text{CH}_2\text{OH}$), 4.26 (1 H, dd, $J = 12.6, 6.4$ Hz, CH_2OH), 4.36 (1 H, dd, $J = 12.6, 7.1$ Hz, CH_2OH), 4.43 (1 H, m, H-3), 4.84 (1 H, m, H-1), 5.84 (1 H, m, $\text{C}=\text{CH}$), 5.91 (1 H, d, $J = 11.0$ Hz, H-7), 6.37 (1 H, d, $J = 11.0$ Hz, H-6). MS m/z (%) 504 (M^+ , 1), 486 (17), 468 (58), 450 (100), 432 (41), 339 (23). UV λ_{max} (EtOH): 246, 254, and 264 nm.

Graphical Manipulations and Ligand Docking. Graphical manipulations were performed using SYBYL (Tripos, St. Louis).

ASSOCIATED CONTENT

Supporting Information

Figures S1–S6 and Tables S1–S3. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Accession Codes

PDB ID codes: 3VT3, 3VT4, 3VT5, 3VT6, 3VT7, 3VT8, and 3VT9.

AUTHOR INFORMATION

Corresponding Authors

*(M.N.) Phone: +81 3 3972 8111 ext 2363. E-mail: makoto-n.str@tmd.ac.jp.

*(S.Y.) Phone: +81 3 3972 8111 ext 2363. E-mail: yamada.vd@image.ocn.ne.jp.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank professor Hector F. DeLuca at Department of Biochemistry, University of Wisconsin—Madison, for kindly providing an expression plasmid of the rVDR-LBD. We thank Dr. Harumi Fukada at Graduate School of Life and Environmental Sciences, Osaka Prefecture University, for guiding the CD spectral study. We thank the beamline staff of the KEK-PF's Structural Biology Research Center for helpful suggestions for acquiring X-ray diffraction images.

ABBREVIATIONS USED

VDR, vitamin D receptor; HVDRR, hereditary vitamin D-resistant rickets; 1,25(OH)₂D₃, 1,25-dihydroxyvitamin D₃; RXR, 9-*cis*-retinoic acid receptor; VDRE, vitamin D-responsive elements; AF-2, activation function 2; DBD, DNA binding domain; LBD, ligand binding domain; LBP, ligand-binding pocket; PPAR γ , peroxisome proliferator-activating receptor γ ; CCR2, CC chemokine receptor 2; CCL2, CC chemokine ligand 2; CCR5, CC chemokine receptor 5

REFERENCES

- DeLuca, H. F. Evolution of our understanding of vitamin D. *Nutr. Rev.* **2008**, *66* (10), S73–S87.
- Jones, G.; Strugnell, S. A.; DeLuca, H. F. Current understanding of the molecular actions of vitamin D. *Physiol. Rev.* **1998**, *78* (4), 1193–1231.
- Baker, A. R.; McDonnell, D. P.; Hughes, M.; Crisp, T. M.; Mangelsdorf, D. J.; Haussler, M. R.; Pike, J. W.; Shine, J.; Omalley, B. W. Cloning and expression of full-length cDNA encoding human vitamin-D receptor. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85* (10), 3294–3298.
- Haussler, M. R.; Whitfield, G. K.; Kaneko, I.; Haussler, C. A.; Hsieh, D.; Hsieh, J. C.; Jurutka, P. W. Molecular mechanisms of vitamin D action. *Calcif. Tissue Int.* **2013**, *92* (2), 77–98.
- Plum, L. A.; DeLuca, H. F. Vitamin D, disease and therapeutic opportunities. *Nat. Rev. Drug Discovery* **2010**, *9* (12), 941–955.
- (a) Thompson, P. D.; Jurutka, P. W.; Haussler, C. A.; Whitfield, G. K.; Haussler, M. R.; Heterodimeric, D. N. A. binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D₃ and inhibited by 9-*cis*-retinoic acid. Evidence for allosteric receptor interactions. *J. Biol. Chem.* **1998**, *273* (14), 8483–8491. (b) Choi, M.; Yamada, S.; Makishima, M. Dynamic and ligand-selective interactions of vitamin D receptor with retinoid X receptor and cofactors in living cells. *Mol. Pharmacol.* **2011**, *80* (6), 1147–1155.
- (a) Malloy, P. J.; Pike, J. W.; Feldman, D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. *Endocr. Rev.* **1999**, *20* (2), 156–188. (b) Malloy, P. J.; Feldman, D. Genetic disorders and defects in vitamin D action. *Endocr. Metab. Clin.* **2010**, *39* (2), 333–346.
- Rochel, N.; Hourai, S.; Moras, D. Crystal structure of hereditary vitamin D-resistant rickets-associated mutant H305Q of vitamin D

nuclear receptor bound to its natural ligand. *J. Steroid Biochem.* **2010**, *121* (1–2), 84–87.

(9) Kristjansson, K.; Rut, A. R.; Hewison, M.; O'Riordan, J. L.; Hughes, M. R. Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. *J. Clin Invest* **1993**, *92* (1), 12–16.

(10) Nguyen, T. M.; Adiceam, P.; Kottler, M. L.; Guillozo, H.; Rizk-Rabin, M.; Brouillard, F.; Lagier, P.; Palix, C.; Garnier, J. M.; Garabedian, M. Tryptophan missense mutation in the ligand-binding domain of the vitamin D receptor causes severe resistance to 1,25-dihydroxyvitamin D. *J. Bone Miner. Res.* **2002**, *17* (9), 1728–1737.

(11) (a) Vanhooke, J. L.; Benning, M. M.; Bauer, C. B.; Pike, J. W.; DeLuca, H. F. Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. *Biochemistry* **2004**, *43* (14), 4101–4110. (b) Nakabayashi, M.; Yamada, S.; Yoshimoto, N.; Tanaka, T.; Igarashi, M.; Ikura, T.; Ito, N.; Makishima, M.; Tokiwa, H.; DeLuca, H. F.; Shimizu, M. Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs: structural basis for vitamin D receptor antagonism and partial agonism. *J. Med. Chem.* **2008**, *51* (17), 5320–5329.

(12) Rachez, C.; Freedman, L. P. Mechanisms of gene regulation by vitamin D-3 receptor: a network of coactivator interactions. *Gene* **2000**, *246* (1–2), 9–21.

(13) (a) Inaba, Y.; Yoshimoto, N.; Sakamaki, Y.; Nakabayashi, M.; Ikura, T.; Tamamura, H.; Ito, N.; Shimizu, M.; Yamamoto, K. A new class of vitamin D analogues that induce structural rearrangement of the ligand-binding pocket of the receptor. *J. Med. Chem.* **2009**, *52* (5), 1438–1449. (b) Inaba, Y.; Nakabayashi, M.; Itoh, T.; Yoshimoto, N.; Ikura, T.; Ito, N.; Shimizu, M.; Yamamoto, K. 22S-butyl-1 α ,24R-dihydroxyvitamin D3: recovery of vitamin D receptor agonistic activity. *J. Steroid Biochem. Mol. Biol.* **2010**, *121* (1–2), 146–150. (c) Fujii, S.; Masuno, H.; Taoda, Y.; Kano, A.; Wongmayura, A.; Nakabayashi, M.; Ito, N.; Shimizu, M.; Kawachi, E.; Hirano, T.; Endo, Y.; Tanatani, A.; Kagechika, H. Boron cluster-based development of potent nonsecosteroidal vitamin D receptor ligands: direct observation of hydrophobic interaction between protein surface and carborane. *J. Am. Chem. Soc.* **2011**, *133* (51), 20933–20941. (d) Yoshimoto, N.; Sakamaki, Y.; Haeta, M.; Kato, A.; Inaba, Y.; Itoh, T.; Nakabayashi, M.; Ito, N.; Yamamoto, K. Butyl pocket formation in the vitamin D receptor strongly affects the agonistic or antagonistic behavior of ligands. *J. Med. Chem.* **2012**, *55* (9), 4373–4381.

(14) Rochel, N.; Wurtz, J. M.; Mitschler, A.; Klaholz, B.; Moras, D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. *Mol. Cell* **2000**, *5* (1), 173–179.

(15) (a) Tocchini-Valentini, G.; Rochel, N.; Wurtz, J. M.; Mitschler, A.; Moras, D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98* (10), 5491–5496. (b) Tocchini-Valentini, G.; Rochel, N.; Wurtz, J. M.; Moras, D. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. *J. Med. Chem.* **2004**, *47* (8), 1956–1961. (c) Hourai, S.; Fujishima, T.; Kittaka, A.; Suhara, Y.; Takayama, H.; Rochel, N.; Moras, D. Probing a water channel near the A-ring of receptor-bound 1 α ,25-dihydroxyvitamin D3 with selected 2 α -substituted analogues. *J. Med. Chem.* **2006**, *49* (17), 5199–5205. (d) Ciesielski, F.; Rochel, N.; Moras, D. Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. *J. Steroid Biochem. Mol. Biol.* **2007**, *103* (3–5), 235–242. (e) Kakuda, S.; Okada, K.; Eguchi, H.; Takenouchi, K.; Hakamata, W.; Kurihara, M.; Takimoto-Kamimura, M. Structure of the ligand-binding domain of rat VDR in complex with the nonsecosteroidal vitamin D3 analogue YR301. *Acta Crystallogr., Sect. F* **2008**, *64* (Pt 11), 970–973.

(16) Shimizu, M.; Miyamoto, Y.; Takaku, H.; Matsuo, M.; Nakabayashi, M.; Masuno, H.; Udagawa, N.; DeLuca, H. F.; Ikura, T.; Ito, N. 2-Substituted-16-ene-22-thia-1 α , 25-dihydroxy-26,27-

dimethyl-19-norvitamin D(3) analogs: Synthesis, biological evaluation, and crystal structure. *Bioorg. Med. Chem.* **2008**, *16* (14), 6949–6964.

(17) (a) Greenfield, N. J. Analysis of the kinetics of folding of proteins and peptides using circular dichroism. *Nat. Protoc.* **2006**, *1* (6), 2891–2899. (b) Greenfield, N. J. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. *Nat. Protoc.* **2006**, *1* (6), 2527–2535.

(18) Strugnell, S. A.; Hill, J. J.; McCaslin, D. R.; Wiefeling, B. A.; Royer, C. A.; DeLuca, H. F. Bacterial expression and characterization of the ligand-binding domain of the vitamin D receptor. *Arch. Biochem. Biophys.* **1999**, *364* (1), 42–52.

(19) Swann, S. L.; Bergh, J.; Farach-Carson, M. C.; Ocasio, C. A.; Koh, J. T. Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. *J. Am. Chem. Soc.* **2002**, *124* (46), 13795–13805.

(20) (a) Kittaka, A.; Kurihara, M.; Peleg, S.; Suhara, Y.; Takayama, H. 2 α -(3-hydroxypropyl)- and 2 α -(3-hydroxypropoxy)-1 α ,25-dihydroxyvitamin D-3 accessible to vitamin D receptor mutant related to hereditary vitamin D-resistant rickets. *Chem. Pharm. Bull.* **2003**, *51* (3), 357–358. (b) Honzawa, S.; Yamamoto, Y.; Yamashita, A.; Sugiura, T.; Kurihara, M.; Arai, M. A.; Kato, S.; Kittaka, A. The 2 α -(3-hydroxypropyl) group as an active motif in vitamin D-3 analogues as agonists of the mutant vitamin D receptor (Arg274Leu). *Bioorg. Med. Chem.* **2008**, *16* (6), 3002–3024.

(21) Ono, K.; Yoshida, A.; Saito, N.; Fujishima, T.; Honzawa, S.; Suhara, Y.; Kishimoto, S.; Sugiura, T.; Waku, K.; Takayama, H.; Kittaka, A. Efficient synthesis of 2-modified 1 α ,25-dihydroxy-19-norvitamin D3 with Julia olefination: high potency in induction of differentiation on HL-60 cells. *J. Org. Chem.* **2003**, *68* (19), 7407–7415.

(22) Yamamoto, K.; Abe, D.; Yoshimoto, N.; Choi, M.; Yamagishi, K.; Tokiwa, H.; Shimizu, M.; Makishima, M.; Yamada, S. Vitamin D receptor: ligand recognition and allosteric network. *J. Med. Chem.* **2006**, *49* (4), 1313–1324.

(23) Yamagishi, K.; Tokiwa, H.; Makishima, M.; Yamada, S. Interactions between 1 α ,25(OH)(2)D-3 and residues in the ligand-binding pocket of the vitamin D receptor: A correlated fragment molecular orbital study. *J. Steroid Biochem.* **2010**, *121* (1–2), 63–67.

(24) Chandra, V.; Huang, P.; Hamuro, Y.; Raghuram, S.; Wang, Y.; Burris, T. P.; Rastinejad, F. Structure of the intact PPAR- γ -RXR-nuclear receptor complex on DNA. *Nature* **2008**, *456* (7220), 350–356.

(25) Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Method Enzymol.* **1997**, *276*, 307–326.

(26) Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr., Sect. D* **1998**, *54* (Pt 5), 905–921.

(27) McRee, D. E. XtalView Xfit - A versatile program for manipulating atomic coordinates and electron density. *J. Struct. Biol.* **1999**, *125* (2–3), 156–165.

(28) Yamamoto, K.; Masuno, H.; Choi, M.; Nakashima, K.; Taga, T.; Ooizumi, H.; Umesono, K.; Sicinska, W.; VanHooke, J.; DeLuca, H. F.; Yamada, S. Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97* (4), 1467–1472.

Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives

Hiroyuki Masuno,^{1,*} Teikichi Ikura,^{1,†} Daisuke Morizono,^{2,*} Isamu Orita,^{*} Sachiko Yamada,[§] Masato Shimizu,^{*} and Nobutoshi Ito^{3,†}

Institute of Biomaterials and Bioengineering,^{*} Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan; Medical Research Institute,[†] Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan; and School of Medicine,[§] Nihon University, Itabashi-ku, Tokyo 173-8610, Japan

Abstract The secondary bile acid lithocholic acid (LCA) and its derivatives act as selective modulators of the vitamin D receptor (VDR), although their structures fundamentally differ from that of the natural hormone $1\alpha,25$ -dihydroxyvitamin D_3 [$1,25(OH)_2D_3$]. Here, we have determined the crystal structures of the ligand-binding domain of rat VDR (VDR-LBD) in ternary complexes with a synthetic partial peptide of the coactivator MED1 (mediator of RNA polymerase II transcription subunit 1) and four ligands, LCA, 3-keto LCA, LCA acetate, and LCA propionate, with the goal of elucidating their agonistic mechanism. LCA and its derivatives bind to the same ligand-binding pocket (LBP) of VDR-LBD that $1,25(OH)_2D_3$ binds to, but in the opposite orientation; their A-ring is positioned at the top of the LBP, whereas their acyclic tail is located at the bottom of the LBP. However, most of the hydrophobic and hydrophilic interactions observed in the complex with $1,25(OH)_2D_3$ are reproduced in the complexes with LCA and its derivatives. Additional interactions between VDR-LBD and the C-3 substituents of the A-ring are also observed in the complexes with LCA and its derivatives. These may result in the observed difference in the potency among the LCA-type ligands.—Masuno, H., T. Ikura, D. Morizono, I. Orita, S. Yamada, M. Shimizu, and N. Ito. Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives. *J. Lipid Res.* 2013. 54: 2206–2213.

Supplementary key words nuclear receptor • structure-function relationship • bile acid • hypercalcemia

The active metabolite of vitamin D_3 , $1,25$ -dihydroxyvitamin D_3 [$1,25(OH)_2D_3$], regulates calcium homeostasis (1). It also promotes cellular differentiation, inhibits cellular proliferation, and suppresses the immune system (2–7). It has been used clinically to treat renal osteodystrophy, vitamin D-dependent rickets type I, and X-linked hypophosphatemic rickets, among other conditions (8–14). Most of its effects are mediated by its specific binding to the vitamin D receptor (VDR), which is a member of nuclear receptor (NR)

super family (15). When $1,25(OH)_2D_3$ is bound to VDR, it activates it by inducing conformational changes. The activated complex, VDR/ $1,25(OH)_2D_3$, binds as a heterodimer with the retinoid X receptor (RXR) to vitamin D response elements located in the promoter region of the target genes. Recruitment of coactivator proteins to this heterodimer is also essential to the transactivation. However, clinical use of $1,25(OH)_2D_3$ is limited because therapeutic doses can give rise to significant hypercalciuria and hypercalcemia (16). A number of synthetic ligands to VDR have been developed for medical use; however, most of them can also cause similar problems because they are derived from $1,25(OH)_2D_3$.

Several synthetic compounds without the vitamin D_3 scaffold have been reported to bind to VDR and have VDR-modulating activities, including growth inhibition of cancer cells and keratinocytes and induction of leukemic cell differentiation, with less calcium mobilization side effects than $1,25(OH)_2D_3$ (17). Therefore, these synthetic compounds are expected to be therapeutics for cancer, leukemia, and psoriasis. Subsequently, Makishima et al. discovered that secondary bile acids, including lithocholic acid (LCA) and its derivatives, also behaved as VDR agonists (18–20). LCA acts as a detergent to stabilize fats for absorption, and it has been implicated in human and experimental animal carcinogenesis. However, the agonistic behavior of LCA as a ligand recognized by VDR was not common knowledge because the structure of LCA is completely different from that of vitamin D_3 . Additional studies showed that VDR had dual functions as a metabolic sensor of bile acids and as an endocrine receptor for $1,25(OH)_2D_3$.

Abbreviations: AcOEt, ethyl acetate; AF2, activation function 2; LBD, ligand-binding domain; LBP, ligand-binding pocket; LCA, lithocholic acid; MED1, mediator of RNA polymerase II transcription subunit 1; NR, nuclear receptor; $1,25(OH)_2D_3$, $1\alpha,25$ -dihydroxyvitamin D_3 ; RMSD, root-mean-square deviation; RXR, retinoid X receptor; VDR, vitamin D receptor.

¹H. Masuno and T. Ikura contributed equally to this work.

²Present address of D. Morizono: Teva API Japan LTD, Minato-ku, Tokyo 105-0001, Japan.

³To whom correspondence should be addressed.
e-mail: ito.str@tmd.ac.jp

Manuscript received 31 March 2013 and in revised form 9 May 2013.

Published, JLR Papers in Press, May 17, 2013
DOI 10.1194/jlr.M038307

Copyright © 2013 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at <http://www.jlr.org>

Both functions are closely related to colon cancer suppression (21). Although theoretical studies were performed to elucidate how LCA binds to $1,25(\text{OH})_2\text{D}_3$, the agonistic mechanism of VDR by LCA was still unclear (18, 22).

Here we determined the crystal structures of the ligand binding domain (LBD) of rat VDR in ternary complexes with a synthetic peptide containing the target sequence of the coactivator MED1 (mediator of RNA polymerase II transcription subunit 1, also known as ARC205 and DRIP205) and the ligands LCA, 3-keto LCA, LCA acetate, and LCA propionate (Fig. 1) to investigate how LCA and its derivatives bind to VDR and how they act as the agonists. The structures reveal that LCA and its derivatives bind to the same ligand-binding pocket (LBP) of VDR that $1,25(\text{OH})_2\text{D}_3$ binds to (23–31), but in the opposite orientation. Comparison of these structures also show how LCA and its derivatives mimic $1,25(\text{OH})_2\text{D}_3$ and give insight into how the C-3 substituents on the A-ring affect the activity of each ligand. The structures also provide a sound basis for designing new compounds using the scaffold of LCA.

MATERIALS AND METHODS

Preparation of LCA ligands

LCA, 3-keto LCA, and LCA acetate were commercially obtained. LCA propionate was synthesized as follows. Boron trifluoride diethyl ether complex (44 μl , 0.33 mmol) was added to a stirred solution of LCA (504.5 mg, 1.34 mmol) in a mixture of propionic anhydride (1.67 ml) and tetrahydrofuran (5 ml) at 0°C, and the resulting solution was stirred at room temperature for 14.5 h. Aqueous sodium hydrogen carbonate was added to this solution, and the reaction mixture was stirred at room temperature for 1 h. Crude LCA propionate was extracted from the reaction mixture with ethyl acetate (AcOEt). The organic layer containing LCA propionate was washed with brine and dried over anhydrous magnesium sulfate, and the solvents were evaporated under house vacuum. The residue was purified by chromatography on silica gel (15 g) with 10% AcOEt/hexane to yield 460 mg (79%) of LCA propionate. The product was recrystallized on AcOEt/hexane.

Protein expression, purification, and crystallization

Rat VDR-LBD (residues 116–423, Δ 165–211) was expressed, purified, and crystallized as described by Vanhooke et al. and Nakabayashi et al. (31, 32). The purity and homogeneity of the protein was assessed by SDS-PAGE. The concentration of the protein was determined by UV absorption at 280 nm with molar extinction coefficients estimated using the method developed by Pace et al. (33). The 13mer synthetic oligopeptide (KNHPM-LMNLLKDN), which corresponds to residues 625–637 of rat MED1, was purchased from World Gene Co., Ltd. (Tokyo, Japan). Each of the four ligands, LCA, 3-keto LCA, LCA acetate, and LCA propionate, was used to prepare a ternary complex of VDR-LBD/peptide/ligand in 10 mM Tris-HCl (pH 7.0), 10 mM dithiothreitol, and 0.02% sodium azide. All the ternary complexes were crystallized at 20°C in a series of precipitant solutions containing 0.1–0.4 M sodium formate, 12–22% (w/v) polyethylene glycol 4000, and 0–10% (v/v) ethylene glycol.

X-ray diffraction data collection and structural analysis

The crystals were flash-frozen using mother liquor supplemented with 10% ethylene glycol. Diffraction data for the ternary complexes were collected at 95 K at beamline BL-6A at the Photon Factory of the High Energy Accelerator Research Organization and were integrated and scaled with HKL2000 (HKL Research, Inc.). The space group for each complex is $C2$; the unit cell dimensions are listed in Table 1 with one complex per asymmetrical unit. The structures were solved by molecular replacement by using the crystal structure of the ternary complex reported by Vanhooke et al. (PDB code: 1RK3) as the search model in CNS (31, 34). Refinement was performed with CNS and XtalView (35).

RESULTS

Overall structures of the ternary complexes

The crystal structures of the ternary complexes of VDR-LBD with LCA and its three derivatives were determined at 1.9–2.2 Å resolution by X-ray crystallography (Table 1 and Fig. 2A). Most of the residues in the complexes were unambiguously determined; however, the N-terminal region (Ala116–Gln122), the middle region (Asp160–Gly164 and Ser212–Leu217), and the C-terminal end (Ser423) of




Fig. 1. Chemical structures of $1,25(\text{OH})_2\text{D}_3$, LCA, and LCA derivatives.

TABLE 1. Data collection and refinement statistics

Ligands	LCA	LCA Acetate	LCA Propionate	3-keto LCA
Data collection				
Unit cell dimensions				
<i>a</i> (Å)	154.5	154.4	154.5	153.8
<i>b</i> (Å)	42.4	42.0	42.8	42.3
<i>c</i> (Å)	41.6	41.5	41.6	41.5
β (degree)	96.8	96.2	96.3	96.4
Resolution (Å)	50–1.9 (1.96–1.90)	50–2.2 (2.28–2.20)	50–2.2 (2.28–2.20)	50–1.9 (1.96–1.90)
Completeness (%)	99.2 (99.9)	99.3 (95.9)	99.6 (96.8)	99.2 (99.8)
Redundancy	3.6 (3.6)	4.3 (4.0)	3.6 (3.4)	3.6 (3.5)
<i>I</i> / σ (<i>I</i>)	43.1 (6.2)	26.2 (4.4)	30.3 (3.9)	41.3 (4.7)
R_{sym} (%)	3.2 (26.4)	5.8 (29.5)	4.5 (35.7)	4.4 (32.9)
Refinement				
R (%)	23.3	22.0	21.1	23.4
R-free (%)	26.3	27.6	26.5	27.9
RMSD bond lengths (Å)	0.0058	0.0068	0.0069	0.0065
RMSD bond angles (degree)	1.25	1.19	1.18	1.22
Number of atoms				
Protein	1925	1942	1942	1926
Peptide	92	92	92	92
Ligand	27	30	31	27
Water	108	49	56	110
Average B factor (Å ²)	41.0	50.1	49.9	43.8

VDR-LBD, and Asp636 and Asn637 of the MED1 peptide were not detected, probably due to fluctuation in these regions. Two more residues at the C-terminal end (Glu421 and Ile422) were also undetectable in the complexes with LCA and 3-keto LCA. Most of these missing residues were previously reported as invisible in studies of other ternary complexes of VDR and are likely a characteristic common to crystals of VDR complexes (23–31).

The overall structures of VDR-LBD in the four complexes are nearly identical (Fig. 2B). The root-mean-square deviations (RMSD) between the proteins in the LCA complex and each of the 3-keto LCA, LCA acetate, and LCA propionate complexes are 0.34, 0.52, and 0.52 Å, respectively, using the C α atoms of Lys123–Met159 and Ser218–Asn420. Furthermore, the RMSD between the proteins in the LCA and 1,25(OH)₂D₃ complexes is 0.49 Å for the overall structure (Fig. 2C). Therefore, no significant structural differences were found among the proteins in the

ternary complexes with LCA, its derivatives, or 1,25(OH)₂D₃ (28, 31).

Structures of the ligands and their interactions with VDR-LBD

Proteins in the NR super family have a common ligand-binding pocket (LBP). Residues in helices 1, 3, 5, 11, and 12, all β -turns, and loops 6–7 and 11–12 form the framework for the LBP of VDR. The natural hormone 1,25(OH)₂D₃ is accommodated in the LBP. In the present study, we observed clear electron density in the LBP, as was previously reported in the complex with 1,25(OH)₂D₃ (Fig. 3A) (28), and crystallographic refinement allowed us unambiguous determination of the structure of LCA and its derivatives in the complex (Figs. 2A and 3A).

Except for their respective substituents, LCA and its three derivatives are accommodated in the LBP of VDR-LBD with almost identical structures. However, their orientation




Fig. 2. Overall structures of ternary complexes of VDR with LCA derivatives. A: Complex structure of VDR with LCA. VDR and MED1 are represented by ribbons, and LCA is represented by a stick. The helices of VDR are numbered after that of the human RXR. B: Superposition of C α traces of the four ternary complexes of VDR with LCA derivatives. Complexes with LCA, 3-keto LCA, LCA acetate, and LCA propionate are represented in red, green, cyan, and magenta, respectively. C: Superposition of C α trace of ternary complexes of VDR with LCA (cyan) and 1,25(OH)₂D₃ (red) complex.




Fig. 3. A: Hydrogen-bonding network between VDR and LCA derivatives, LCA, 3-keto LCA, LCA acetate, and LCA propionate. The purple fishnet is the $F_o - F_c$ omit-annealed difference Fourier electron-density map contoured at 3σ level from the average of the map. The oxygen atoms of water are represented by red spheres. B: Superposition of the four LCA derivatives in VDR complexes. LCA, 3-keto LCA, LCA acetate, and LCA propionate are represented in red, green, cyan, and magenta, respectively. C: Superposition of LCA acetate (green) and 1,25(OH)₂D₃ (magenta) in VDR complexes.

is opposite to that of 1,25(OH)₂D₃ in both the horizontal and vertical planes (Fig. 3C). The 24-carboxyl group is directed toward the β -turns, and the β -face of the steroid is directed toward helix 7 in the bottom of the LBP, while the A-ring faces helix 12 (Fig. 2A). LCA forms three hydrogen bonds at the carboxyl group. One oxygen atom of the carboxyl group directly forms hydrogen bonds with the hydroxyl groups in the side chains of Tyr143 in helix 1 (the distance between the oxygen atoms of the carboxyl group and the hydroxyl group is 2.46 Å) and Ser274 in helices 4/5 (the distance between the oxygen atoms of the carboxyl group and the hydroxyl group is 2.76 Å). The other oxygen atom of the same carboxyl group interacts via a water molecule (the distance between the oxygen atoms of the water and the carboxyl group is 2.69 Å), with the hydroxyl group in the side chain of Ser233 in helix 3 and the guanidinium group in the side chain of Arg270 in helix

4/5 (the distance between the water molecule and these residues are 2.92 Å and 3.01 Å, respectively) (Fig. 3A). These hydrogen bonds are also observed in the other three complexes. The four rings of the steroid in each of the complexes interact with hydrophobic residues in the LBP through hydrophobic interactions. There are 12 residues (Leu226, Leu229, Val230, Ile264, Ile276, Met268, Trp282, Val296, Ala299, Leu305, Ile306, and Leu309) distributed within 4.3 Å from the rings. Such hydrophobic interactions are also conserved in the other complexes.

Hydrogen bonds between VDR and the ligands are also observed at the other end of the ligands, the C-3 position of the A-ring. The four ligands differ in their substituents at this position. The hydroxyl group of LCA, the carbonyl group of 3-keto LCA, the propionyl group of LCA propionate, and the acetyl group of LCA acetate interact with residues in helix 6, loop 6-7, and helix 11 (Figs. 2A and 3A). In the

complexes with LCA and 3-keto LCA, the oxygen atoms of the respective hydroxyl and carbonyl groups of the substituents interact via a water-mediated hydrogen bond with the nitrogen atoms of imidazole rings of His301 in helix 6 and His393 in helix 11. In contrast, in the complex with LCA acetate, the oxygen atom of the acetyl group directly forms a hydrogen bond with the nitrogen atom of the imidazole ring of His301. In the complex with LCA propionate, the oxygen atom of the propionyl group also directly forms a hydrogen bond with the nitrogen atom of the imidazole ring of His393. Furthermore, the alkyl parts of the two substituents interact with the aromatic rings of Tyr397 in helix 11 and Phe418 in helix 12 and with the side chains of Leu410 and Val414 in helix 12, stabilizing the binding of the two derivatives to the LBP of VDR-LBD (Fig. 3A). From this viewpoint, LCA propionate may be the most effective of the four ligands because it has the longest alkyl part in the substituent.

Structure of the MED1 peptide

NR super family proteins generally include two domains for two types of transactivations, a constitutive activation function (AF-1) and a ligand-dependent activation function (AF-2). The AF-2 domain of the VDR-LBD consists of helices 3, 4, and 12, and loop 3–4, and it interacts with the LXXLL motif known as the NR-box. In the present study, we synthesized a peptide containing the target sequence of the MED1 coactivator and determined the structure of the peptide in the four ternary complexes to investigate whether or not LCA and its derivatives affect coactivator binding. The peptide binds to the AF-2 domain in each of the four complexes similar to the complex with $1,25(\text{OH})_2\text{D}_3$. Although two residues of the peptide, Asp636 and Asn637, have no detectable structure as described above, the rest of the peptide forms an α -helix with a kink at Pro628 in each complex (Fig. 4A). The structure of the peptide in the four complexes is nearly identical. The RMSDs between the peptides in the LCA complex and the 3-keto LCA, LCA acetate, and LCA propionate complexes are 0.22, 0.58, and 0.69 Å, respectively, using the C α atoms of Lys625–Lys635. The structure of the peptide in the LCA complex was also compared

with that in the $1,25(\text{OH})_2\text{D}_3$ complex. The RMSD between the two peptides was calculated at 0.76 Å, indicating no significant structural differences among the peptides in the ternary complexes with LCA, its derivatives, and $1,25(\text{OH})_2\text{D}_3$ (Fig. 4B) (28, 31).

The AF-2 domain forms a shallow pit consisting of five hydrophobic residues: Ile238 in helix 3, Ile256 in helix 4/5, Leu259 in helix 4/5, Leu413 in helix 12, and Val417 in helix 12. The peptide binds to this pit through the hydrophobic interactions between the LXXLL motif of the peptide and the complementary pit of the protein. The polar side chains of Lys242 in helix 3 and Glu416 in helix 12 also facilitate the binding of the peptide by clamping it on the both edges of the AF-2 domain (a charge clamping). Two hydrogen bonds are formed between the oxygen atom of the side chain carboxyl group of Glu416 and the amide nitrogen of Met629, and the nitrogen atom of the side chain amino group of Lys242 and the carbonyl oxygen of Leu633. All these interactions observed in the present study are the same as those seen in the complex with $1,25(\text{OH})_2\text{D}_3$. Therefore, these results indicate that the interactions between the coactivator MED1 and the AF-2 domain are well conserved in the ternary complexes with LCA and its derivatives.

DISCUSSION

Since the discovery of its function as an agonist of VDR, LCA has been expected to be used a vitamin D alternative, especially because LCA appears to activate VDR without causing hypercalcemia. However, because the functional mechanism of LCA was still unclear, LCA derivatives with higher activities have been found mainly by trial and error. In the present study, we determined the structures of ternary complexes of VDR-LBD with LCA and its derivatives and elucidated how they bind to VDR-LBD.

LCA and its derivatives bind to the same LBP that $1,25(\text{OH})_2\text{D}_3$ binds to. However, their orientation is opposite to that of $1,25(\text{OH})_2\text{D}_3$ (Fig. 3C). Its A-ring was set on the inlet of the LBP, while its 24-carboxyl group wedged




Fig. 4. Structures of MED1 peptides in VDR complexes. MED1 peptide and Lys242 and Glu416 of each VDR complex are represented by sticks; the other parts are represented by ribbons. A: Superposition of MED1 peptides in VDR complexes with LCA (red), 3-keto LCA (green), LCA acetate (cyan), and LCA propionate (magenta). B: Superposition of MED1 peptides in VDR complexes with LCA (magenta) and $1,25(\text{OH})_2\text{D}_3$ (white carbons).

itself into the LBP. Interestingly this orientation is the same as that of 6 α -ethyl-chenodeoxycholic acid (6 α -ethyl-CDCA) in the farnesoid X receptor (FXR) (36). LCA and its derivatives are similar in size (14–16 Å × 5 Å × 3 Å; length × width × thickness) to natural 1,25(OH)₂D₃ (approximately 15 Å × 5 Å × 2 Å), and although their shapes are somewhat different, the nonplanar *cis* A/B rings of the steroid scaffold of LCA mimic the curvature of the 9,10-secosteroid portion of 1,25(OH)₂D₃ (Fig. 3C). Often, the size seems to be critical to the agonistic activity of a ligand. Agonistic ligands induce a conformational change of loop 11–12 to bring helix 12 into the active conformation, which is stabilized by hydrophobic interactions between the ligand and Val418 and Phe422 (Val414 and Phe418 of rat VDR, respectively). This conformation creates the AF-2 surface and allows the coactivator to bind, which is required for the VDR activity. Large ligands could collide with helix 12 and destabilize the active conformation. Indeed, several larger ligands have been reported to show antagonistic activity instead of agonistic activity (32, 37).

Despite their opposite orientation, LCA and its derivatives can reproduce the interactions between VDR and 1,25(OH)₂D₃, which consists of a hydrophobic secosteroid framework and three polar groups. The polar groups are located at the both ends of the ligand and stabilize ligand binding through several hydrogen bonds, while the hydrophobic secosteroid frame just fits the hydrophobic tunnel of the LBP. In the complex with 1,25(OH)₂D₃, the A-ring of 1,25(OH)₂D₃ deeply wedges itself into the LBP and its 25-hydroxyl group is set on the inlet of the LBP. There are two polar groups at the C-1 and C-3 positions of the A-ring of 1,25(OH)₂D₃, whose oxygen atoms form two pairs of bifurcated hydrogen bonds with the side chains of Tyr143 and Ser274, and Ser233 and Arg270, respectively. Furthermore, the 25-hydroxyl group of 1,25(OH)₂D₃ also forms a bifurcated hydrogen bond with the nitrogen atoms of the imidazole rings of His301 and His393. In contrast, LCA and its derivatives consist of the hydrophobic steroid framework and two polar groups at the both ends (Fig. 1). However, they maintain most of the hydrogen bonds between the ligand and the protein by exchanging the hydrogen-bonding partners between the A-ring and the carboxyl group. Two oxygen atoms of the 24-carboxyl group form, with the help of a water molecule, two pairs of bifurcated hydrogen bonds directly with the side chains of Tyr143 and Ser274, and indirectly with Ser233 and Arg270, respectively. The hydrogen bonds with the nitrogen atoms of the imidazole rings of His301 and His393 are partially formed, depending on the substituents at the C-3 position of the A-ring. Therefore, the hydrogen-bonding network between the ligand and the protein is essentially the same for both LCA and 1,25(OH)₂D₃, even though their orientations are opposite. Adachi et al. also indicated the importance of the hydrogen-bonding network for agonistic activity by showing that esterification of the carboxyl group of LCA weakened its agonistic activity (18).

Although LCA mimicked the dimensions and chemical properties of 1,25(OH)₂D₃ as discussed above, its affinity is much lower than 1,25(OH)₂D₃. In a competitive binding

assay using VDR fused to glutathione S-transferase, IC₅₀ values were estimated as 0.08 nM and 300 μM for 1,25(OH)₂D₃ and LCA, respectively (19). As the accessible surface areas of the hydrophobic surface of LCA and 1,25(OH)₂D₃ are 371 Å² and 442 Å², respectively, the total hydrophobic interaction of LCA with VDR would be expected to be smaller than that of 1,25(OH)₂D₃. Also the simple difference of the size between LCA (C₂₄H₄₀O₃) and 1,25(OH)₂D₃ (C₂₇H₄₄O₃) suggests that the LBP accommodates LCA somewhat loosely. Such a feature allows several water molecules to penetrate the LBP of VDR. One of the water molecules is involved in the hydrogen bond network around the 24-carboxyl group. Another water molecule is incorporated in the hydrogen bond network around the C-3 position of the A-ring in the complex with LCA. However, given the affinity analyses mentioned above, the interactions mediated by hydrogen bonding seem to be less important for stabilizing the complex than the hydrophobic interactions.

The substituents at the C-3 position of the A-ring of LCA also affect the activation of human VDR, and LCA acetate and LCA propionate are more potent agonists than LCA and 3-keto LCA (18, 19, 22, 38). The binding assay mentioned above showed that IC₅₀ values for LCA acetate and LCA propionate are 30 μM, about 10 times more potent than LCA (19). Another cotransfection assay showed LCA acetate (EC₅₀ = 0.40 μM) is about 30 times more effective than LCA (EC₅₀ = 12.1 μM), whereas 3-keto LCA (EC₅₀ = 6.8 μM) is comparable to LCA (18). Our crystal structures show that the C-3 substituents of the former derivatives interact directly with VDR via a hydrogen bond, while the latter ones require a water molecule to form indirect hydrogen bonds with VDR. In addition, the alkyl part of these acyl groups interacts with the hydrophobic residues of VDR, including Val418 and Phe422 (Val414 and Phe418 of rat VDR, respectively), which are key residues in the VDR activation mechanism described above. These interactions are probably the reason for the higher potency of these two ligands because this valine is not directly involved in the interaction with the ligands in the case of LCA and 3-keto LCA. These additional interactions at the C-3 position may also explain some of the mutation analyses; the human VDR-S275A and S278A mutations (corresponding to S271A and S274A of rat VDR, respectively) almost completely abolished the activity of LCA, whereas they were still activated by LCA acetate (18). The extra interactions at the C-3 position compensate for the loss of the hydrogen bond due to the mutation to some extent.

Some of the other results from the mutation analyses could also be explained from our structure (18, 19, 22, 38). The VDR-S237M mutant (S233M of rat VDR) can respond to LCA but not to 1,25(OH)₂D₃. The serine residue is directly interacts with the A-ring of 1,25(OH)₂D₃ through a hydrogen bond, and the mutation to methionine would not only lose the capability of the interaction but also hinder the ligand binding. On the other hand, the bulky A-ring is replaced by a linear alkyl group in LCA (Fig. 3C), creating enough room to accommodate in the methionine. In contrast, the VDR-S278V mutant (S274V of rat VDR) is

activated by $1,25(\text{OH})_2\text{D}_3$ but not by LCA. The side chain of the serine also directly interacts with the hydroxyl group of the A-ring of $1,25(\text{OH})_2\text{D}_3$ and the carboxyl group of LCA. The mutation to valine would lose the hydrogen bond, but there is enough room to accommodate the replaced side chain in both cases. LCA might disfavor the mutant that would bring the hydrophobic valine close to the negative charge of the carboxyl group.


The role of His305 (His301 of rat VDR) in the interactions with the LCA-related ligands seems more complicated. Although LCA and 3-keto LCA interact with His305 in a very similar manner (Fig. 3A), the VDR-H305A (H301A of rat VDR) mutant significantly diminishes the LCA activity but has little effect on activation by LCA acetate or 3-keto LCA. The indole ring lies almost parallel to the A-ring of LCA, making van der Waals contacts. It is also involved in the hydrogen bond directly (LCA acetate) or indirectly (LCA and 3-keto LCA). These interactions are almost the only interactions between the ligand and loop 6–7, and the mutation to alanine may perhaps trigger a large conformational change of the loop, which could even expose the ligand to the solvent.

Although LCA activates VDR, it functions differently from $1,25(\text{OH})_2\text{D}_3$; for example, it does not induce hypercalcemia. The most prominent difference in the ligand binding between $1,25(\text{OH})_2\text{D}_3$ and the LCA-related ligands reported here are the pattern of the hydrogen bonds with Ser233 in helix 3 and Arg270 in helix 4/5. While 1α -hydroxyl group of $1,25(\text{OH})_2\text{D}_3$ directly forms the hydrogen bonds with these two residues, all the LCA-related ligands studied here require a water molecule to form indirect hydrogen bonds with them, which is likely to weaken the interaction with VDR. Also, replacing the A-ring of $1,25(\text{OH})_2\text{D}_3$ with a linear alkyl group seems to loosen the hydrophobic interactions around it, as highlighted by the VDR-S237M mutant discussed above. These differences may affect the structure of the AF-2 surface and, therefore, the interactions between VDR and the coactivators statically and/or dynamically.

However, we did not detect significant differences in the interactions between VDR and the coactivator peptide. One possible reason is the crystal packing. The coactivator peptide not only interacts with VDR but also plays an important role in the crystal packing, and even antagonists could be trapped in its active form at high concentrations as in the crystallization conditions (32). Thus the structural differences that may be caused by LCA could have been suppressed by the crystal packing. The possibility that LCA behaves differently from $1,25(\text{OH})_2\text{D}_3$ through a nonstructural mechanism also cannot be excluded. Their metabolic behavior and/or cellular distribution would be different in vivo, causing the functional differences. To rationally elucidate the underlying reason for the difference in the agonistic activity between the ligands, it will be necessary to analyze the higher-ordered complexes, perhaps using full-length VDR. The crystal structures reported here nonetheless have shown the similarities and differences between LCA-related ligands and $1,25(\text{OH})_2\text{D}_3$ in their interactions with VDR and should provide a sound

basis for the design of new ligands based on LCA, hopefully with better pharmaceutical features.

Data deposition

The coordinates of the determined structures have been deposited in the Protein Data Bank with accession numbers 3W5P, 3W5Q, 3W5R, and 3W5T for the LCA, 3keto-LCA, LCA acetate, and LCA propionate complexes, respectively. 

The authors thank Professor H. Kagechika and Professor H. Tamamura of Tokyo Medical and Dental University for supporting this research project. The authors also thank the technical staff at the Photon Factory of the High Energy Accelerator Research Organization for maintenance of the beam line.

REFERENCES

1. Haussler, M. R., G. K. Whitfield, C. A. Haussler, J. C. Hsieh, P. D. Thompson, S. H. Selznick, C. E. Dominguez, and P. W. Jurutka. 1998. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *J. Bone Miner. Res.* **13**: 325–349.
2. Abe, E., C. Miyaura, H. Sakagami, M. Takeda, K. Konno, T. Yamazaki, S. Yoshiki, and T. Suda. 1981. Differentiation of mouse myeloid leukemia cells induced by $1\alpha,25$ -dihydroxyvitamin D₃. *Proc. Natl. Acad. Sci. USA.* **78**: 4990–4994.
3. DeLuca, H. F. 2004. Overview of general physiologic features and functions of vitamin D. *Am. J. Clin. Nutr.* **80**(Suppl.): 1689–1696.
4. Hosomi, J., J. Hosoi, E. Abe, T. Suda, and T. Kuroki. 1983. Regulation of terminal differentiation of cultured mouse epidermal cells by $1\alpha,25$ -dihydroxyvitamin D₃. *Endocrinology.* **113**: 1950–1957.
5. Lemire, J. M. 1992. Immunomodulatory role of $1,25$ -dihydroxyvitamin D₃. *J. Cell. Biochem.* **49**: 26–31.
6. Smith, E. L., N. C. Walworth, and M. F. Holick. 1986. Effect of $1\alpha,25$ -dihydroxyvitamin D₃ on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. *J. Invest. Dermatol.* **86**: 709–714.
7. Tanaka, H., E. Abe, C. Miyaura, T. Kuribayashi, K. Konno, Y. Nishii, and T. Suda. 1982. $1\alpha,25$ -Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). *Biochem. J.* **204**: 713–719.
8. Bortman, P., M. A. Figueira, M. L. Katayama, I. M. Snitcovsky, and M. M. Brentani. 2002. Antiproliferative effects of $1,25$ -dihydroxyvitamin D₃ on breast cells: a mini review. *Braz. J. Med. Biol. Res.* **35**: 1–9.
9. Fraser, D., S. W. Kooh, H. P. Kind, M. F. Holick, Y. Tanaka, and H. F. DeLuca. 1973. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25 -hydroxyvitamin D to $1\alpha,25$ -dihydroxyvitamin D. *N. Engl. J. Med.* **289**: 817–822.
10. Glorieux, F. H., P. J. Marie, J. M. Pettifor, and E. E. Delvin. 1980. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. *N. Engl. J. Med.* **303**: 1023–1031.
11. Hayes, C. E. 2000. Vitamin D: a natural inhibitor of multiple sclerosis. *Proc. Nutr. Soc.* **59**: 531–535.
12. Konety, B. R., and R. H. Getzenberg. 2002. Vitamin D and prostate cancer. *Urol. Clin. North Am.* **29**: 95–106, ix.
13. Lambert-Allardt, C. 1991. Is there a role for vitamin D in osteoporosis? *Calcif. Tissue Int.* **49**(Suppl.): S46–S49.
14. Langner, A., H. Verjans, V. Stapor, M. Mol, and M. Fraczykowska. 1993. Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. *Br. J. Dermatol.* **128**: 566–571.
15. Yamada, S., M. Shimizu, and K. Yamamoto. 2003. Vitamin D receptor. *Endocr. Dev.* **6**: 50–68.
16. Bouillon, R., W. H. Okamura, and A. W. Norman. 1995. Structure-function relationships in the vitamin D endocrine system. *Endocr. Rev.* **16**: 200–257.
17. Boehm, M. F., P. Fitzgerald, A. Zou, M. G. Elgort, E. D. Bischoff, L. Mere, D. E. Mais, R. P. Bissonnette, R. A. Heyman, A. M. Nadzan, et al. 1999. Novel nonsecosteroidal vitamin D mimics exert

VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D₃. *Chem. Biol.* **6**: 265–275.

18. Adachi, R., Y. Honma, H. Masuno, K. Kawana, I. Shimomura, S. Yamada, and M. Makishima. 2005. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. *J. Lipid Res.* **46**: 46–57.
19. Ishizawa, M., M. Matsunawa, R. Adachi, S. Uno, K. Ikeda, H. Masuno, M. Shimizu, K. Iwasaki, S. Yamada, and M. Makishima. 2008. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. *J. Lipid Res.* **49**: 763–772.
20. Makishima, M., T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, and D. J. Mangelsdorf. 2002. Vitamin D receptor as an intestinal bile acid sensor. *Science*. **296**: 1313–1316.
21. Degirolamo, C., S. Modica, G. Palasciano, and A. Moschetta. 2011. Bile acids and colon cancer: solving the puzzle with nuclear receptors. *Trends Mol. Med.* **17**: 564–572.
22. Choi, M., K. Yamamoto, T. Itoh, M. Makishima, D. J. Mangelsdorf, D. Moras, H. F. DeLuca, and S. Yamada. 2003. Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning mutational analysis. *Chem. Biol.* **10**: 261–270.
23. Ciesielski, F., N. Rochel, A. Mitschler, A. Kouzmenko, and D. Moras. 2004. Structural investigation of the ligand binding domain of the zebrafish VDR in complexes with 1 α ,25(OH)₂D₃ and Gemini: purification, crystallization and preliminary X-ray diffraction analysis. *J. Steroid Biochem. Mol. Biol.* **89–90**: 55–59.
24. Eelen, G., L. Verlinden, N. Rochel, F. Claessens, P. De Clercq, M. Vandewalle, G. Tocchini-Valentini, D. Moras, R. Bouillon, and A. Verstuyf. 2005. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. *Mol. Pharmacol.* **67**: 1566–1573.
25. Hourai, S., T. Fujishima, A. Kittaka, Y. Suhara, H. Takayama, N. Rochel, and D. Moras. 2006. Probing a water channel near the A-ring of receptor-bound 1 α ,25-dihydroxyvitamin D₃ with selected 2 α -substituted analogues. *J. Med. Chem.* **49**: 5199–5205.
26. Rochel, N., S. Hourai, X. Perez-Garcia, A. Rumbo, A. Mourino, and D. Moras. 2007. Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol. *Arch. Biochem. Biophys.* **460**: 172–176.
27. Rochel, N., J. M. Wurtz, A. Mitschler, B. Klaholz, and D. Moras. 2000. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. *Mol. Cell.* **5**: 173–179.
28. Shimizu, M., Y. Miyamoto, H. Takaku, M. Matsuo, M. Nakabayashi, H. Masuno, N. Udagawa, H. F. DeLuca, T. Ikura, and N. Ito. 2008. 2-Substituted-16-ene-22-thia-1 α ,25-dihydroxy-26,27-dimethyl-19-norvitamin D₃ analogs: synthesis, biological evaluation, and crystal structure. *Bioorg. Med. Chem.* **16**: 6949–6964.
29. Tocchini-Valentini, G., N. Rochel, J. M. Wurtz, A. Mitschler, and D. Moras. 2001. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. *Proc. Natl. Acad. Sci. USA.* **98**: 5491–5496.
30. Tocchini-Valentini, G., N. Rochel, J. M. Wurtz, and D. Moras. 2004. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. *J. Med. Chem.* **47**: 1956–1961.
31. Vanhooke, J. L., M. M. Benning, C. B. Bauer, J. W. Pike, and H. F. DeLuca. 2004. Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D₃ hormone analogues and a LXXLL-containing coactivator peptide. *Biochemistry*. **43**: 4101–4110.
32. Nakabayashi, M., S. Yamada, N. Yoshimoto, T. Tanaka, M. Igarashi, T. Ikura, N. Ito, M. Makishima, H. Tokiwa, H. F. DeLuca, et al. 2008. Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs: structural basis for vitamin D receptor antagonism and partial agonism. *J. Med. Chem.* **51**: 5320–5329.
33. Pace, C. N., F. Vajdos, L. Fee, G. Grimsley, and T. Gray. 1995. How to measure and predict the molar absorption coefficient of a protein. *Protein Sci.* **4**: 2411–2423.
34. Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, et al. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr. D Biol. Crystallogr.* **54**: 905–921.
35. McRee, D. E. 1999. XtalView/Xfit—a versatile program for manipulating atomic coordinates and electron density. *J. Struct. Biol.* **125**: 156–165.
36. Mi, L. Z., S. Devarakonda, J. M. Harp, Q. Han, R. Pellicciari, T. M. Willson, S. Khorasanizadeh, and F. Rastinejad. 2003. Structural basis for bile acid binding and activation of the nuclear receptor FXR. *Mol. Cell.* **11**: 1093–1100.
37. Inaba, Y., M. Nakabayashi, T. Itoh, N. Yoshimoto, T. Ikura, N. Ito, M. Shimizu, and K. Yamamoto. 2010. 22S-butyl-1 α ,24R-dihydroxyvitamin D₃: recovery of vitamin D receptor agonistic activity. *J. Steroid Biochem. Mol. Biol.* **121**: 146–150.
38. Sato, H., A. Macchiarulo, C. Thomas, A. Gioiello, M. Une, A. F. Hofmann, R. Saladin, K. Schoonjans, R. Pellicciari, and J. Auwerx. 2008. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. *J. Med. Chem.* **51**: 1831–1841.

Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating

Teikichi Ikura¹ and Nobutoshi Ito

Laboratory of Structural Biology, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan

¹To whom correspondence should be addressed.
E-mail: ikura.str@tmd.ac.jpReceived May 8, 2013; revised June 6, 2013;
accepted June 16, 2013

Edited by Haruki Nakamura

The Alzheimer's disease-related protein, tau, aggregates into neurofibrillary tangles when it is hyperphosphorylated. The amino acid sequence included in the third repeat (R3) of the microtubule-binding region is suspected to be the main factor for tau aggregation. Here, we synthesized a 31-residue oligopeptide, corresponding to the R3 region, and characterized its aggregation propensity under various conditions. This peptide aggregated even in the absence of an aggregation-inducing molecule at a low salt concentration, while it did not form any aggregates at a high salt concentration. This suggests that hydrophilic interactions are the main cause of aggregation. We then investigated the function of FK506-binding protein (FKBP) 12, which is known to accumulate in neurofibrillary tangles *in vivo*, on aggregation of the R3 peptide and found that FKBP12 completely prevented the peptide from aggregating at a concentration ratio of 1 : 4 (peptide:FKBP12). FKBP12 also restored the oligomer of the peptide to its monomeric status. Mutational studies on the catalytic center of FKBP12 indicated that peptidyl-prolyl isomerase activity of FKBP12 was essential for prevention of aggregation. Assuming that the propensity of aggregation of the peptide is different in each *cis*-*trans*-isomer, we propose that the aggregation behavior of the R3 peptide can be theoretically described with a simple kinetic scheme, in which only the *cis*-isomer can aggregate and FKBP12 catalyzes isomerization of the peptide in both the monomeric and aggregative states.

Keywords: Alzheimer's disease/FK506 binding protein 12/ neurofibrillary tangles/peptidyl-prolyl isomerase activity/tau protein

Introduction

The tau protein is essential for assembly and stability of microtubule, which mainly consists of two types of tubulin (Weingarten *et al.*, 1975; Lindwall and Cole, 1984). Hyperphosphorylation of tau abolishes its ability to bind to tubulin and promote microtubule assembly (Bramblett *et al.*, 1993; Yoshida and Ihara, 1993). When it is released from tubulin, phosphorylated tau protein aggregates into neurofibrillary tangles (NFTs), which are the neuropathological hallmarks of Alzheimer's disease (AD) (Goedert *et al.*, 1988; Morishima-Kawashima *et al.*, 1995). Perez *et al.* (2001)

showed that the microtubule-binding domain (MBD) of tau protein is involved in the core of NFT (Fig. 1). The ability to aggregate, however, was impaired in a variant of 3-repeat isoforms of tau protein, which lacked six residues Val306-Gln307-Ile308-Val309-Tyr310-Lys311, in the third region (R3), even though it was hyperphosphorylated. This suggests that the main factor for aggregation of tau protein is included in R3 (Perez *et al.*, 2007).

Dissection analysis was carried out for the MBD. Peptides corresponding to each of the four regions of the MBD (R1, R2, R3 and R4) and various combinations of these (R1–R3, R2–R3, R3–R4, R1–R2–R3, R1–R2–R3–R4 etc.) were chemically synthesized, and their aggregations were investigated by fluorescence-coupled circular dichroism and dynamic light scattering (Mizushima *et al.*, 2006; Zhou *et al.*, 2006; Sugino *et al.*, 2009). Only the peptides including R2 and/or R3 formed filaments in the presence of heparin, although their aggregation processes differed from each other.

A study in 1997 found that a peptidyl-prolyl isomerase (PPIase), Pin1, which specifically isomerized phosphorylated serine or threonine preceding a proline (pSer/Thr-Pro), restored the function of Alzheimer-associated phosphorylated tau protein (Yaffe, 1997; Lu *et al.*, 1999). Pin1 catalyzed prolyl isomerization of specific pSer/Thr-Pro motifs in tau protein to facilitate their dephosphorylation by a Pro-directed phosphatase, PP2A, which was conformation-specific and effectively dephosphorylated only the *trans*-pSer/Thr-Pro isomer (Zhou *et al.*, 2000). A high aggregation-prone (*cis*) isomer was converted to a low aggregation-prone (*trans*) isomer by PPIase activity of Pin1 (Nakamura *et al.*, 2012). As a result, the dephosphorylated tau protein regained ability for assembly and stability of microtubule (Zhou *et al.*, 2000). Phosphorylated sites were mapped on the sequences of various isoforms of tau protein (Brion *et al.*, 1993; Goedert *et al.*, 1993; Kopke *et al.*, 1993; Morishima-Kawashima *et al.*, 1995; Liu *et al.*, 2007). Pin1 worked on several specific sites of at least 30 phosphorylated sites (Lu *et al.*, 1999; Hamdane *et al.*, 2002; Smet *et al.*, 2004; Hamdane *et al.*, 2006; Landrieu *et al.*, 2010; Ogawa *et al.*, 2010). Phosphorylated Thr231-Pro232 was identified as the major target of Pin1 (Lu *et al.*, 1999; Zhou *et al.*, 2000; Nakamura *et al.*, 2012). No pSer/Thr-Pro motif, however, exists on the MBD, indicating that Pin1 does not directly affect the highest aggregation region of tau protein.

Recently, FK506-binding protein (FKBP) 12, FKBP51 and FKBP52 were found to bind to tau (Cao and Konsolaki, 2011). FKBP51 and FKBP52 are PPIases bound to FK506 and rapamycin (Siekierka *et al.*, 1989), and they generally show much higher PPIase activity on Xaa-Pro (Xaa; a standard amino acid residue) motifs than on pSer/Thr-Pro motif (Yaffe, 1997). Both of the large FKBP51 (51 kDa) and FKBP52 (52 kDa), are involved in tau turnover (Chambraud *et al.*, 2010; Jinwal *et al.*, 2010). Although FKBP51 and FKBP52 have very similar structure and both are mostly ubiquitously expressed, these proteins exert opposite effects on tau protein. FKBP51 promotes the association of tau protein with Hsp90, leading to




Fig. 1. Schematic diagram of four repeat regions in the microtubule-binding domain (MBD) of tau protein and amino acid sequences of the third and fourth repeats (R3 and R4). Labeled fluorophores used in the present study are also shown to the left of the sequences.

dephosphorylation and proper recycling of tau protein (Jinwal *et al.*, 2010), whereas FKBP52 binds directly and specifically to tau protein, preventing tau protein from binding to tubulin (Chambraud *et al.*, 2010). On the other hand, the smaller FKBP12 (12 kDa) co-localized with NFT in AD brains, suggesting that FKBP12 interacted with abnormal forms of tau protein (Harding *et al.*, 1989; Sugata *et al.*, 2009). It is possible that FKBP12 interacts with the MBD of tau protein because the MBD contains eight Xaa-Pro motifs. Assuming each *cis/trans*-isomer of the Xaa-Pro motif in the MBD corresponds with the normal or abnormal form of tau, as seen for phosphorylated Thr231-Pro232, FKBP12 might be able to restore abnormal forms of tau protein to its normal forms. Thus, FKBP12 is a candidate to regulate tau protein by interacting with its MBD.

Here, we synthesized a peptide that corresponds to the R3 region of tau protein (R3 peptide) and investigated whether or not FKBP12 prevents its aggregation *in vitro* under various conditions by fluorescence and dynamic light scattering measurements. In the present study, we focused on the early stage of aggregation of the R3 peptide because Pin1 affected tau protein at the early stage of aggregation (Ramakrishnan *et al.*, 2003; Nakamura *et al.*, 2012). The early stage of aggregation, however, is poorly understood, particularly because of the difficulty of its detection. Thus, we labeled the R3 peptide with fluorescein to increase sensitivity. First, we checked if fluorescein did not change the nature of the peptide with respect to aggregation and investigated the aggregation mechanism for the R3 peptide by measuring aggregation under various conditions. We then measured the aggregation of the R3 peptide in the presence of FKBP12 in order to investigate the aggregation inhibitory activity of FKBP12. As a result, higher the concentration of FKBP12 became, less the aggregation of the R3 peptides was detected. Next, we investigated the aggregation inhibitory mechanism by FKBP12 by introducing two types of mutations Val55 → Arg and Tyr82 → Lys. The former mutation increased the activity 11-fold, whereas the latter decreased it 7-fold. We globally analyzed the relationship between the PPIase activity of FKBP12 and the aggregation inhibitory activity. On the basis of these results, we concluded that the PPIase activity of FKBP12 prevented the R3 peptide from aggregating.

Materials and methods

Chemicals

Heparin sodium was of Wako Special Grade from Wako Pure Chemical Industries Ltd. All other chemicals were of guaranteed reagent grade.

Peptides and proteins

The R3 and R4 peptides, the sequences of which are shown in Fig. 1, were chemically synthesized using a solid-phase peptide synthesizer (Sigma Aldrich Japan K.K.). A fluorescein and an amide group were attached to the N-terminal amide group of Val1 and the C-terminal carboxyl group of Glu31 in the R3 peptide, respectively. TAMRA and amide group were attached to the N-terminal amide group of Val1 and the C-terminal carboxyl group of Asn32 in the R4 peptide, respectively. Their purity was 94.4 and 98.7% for the R3 and R4 peptides, respectively, as determined by mass spectrometry. These peptides were obtained in lyophilized form.

Wild-type human FKBP12 and its two mutants, FKBP12/Val55Arg and FKBP12/Tyr82Lys, were expressed and purified as described previously (Ikura and Ito, 2007).

Time-dependent fluorescence measurement

Aggregation of the R3 peptide quenched the fluorescence of fluorescein attached to the peptide; as the peptide became more aggregated, the change in fluorescence intensity became larger, as shown in Fig. 2a. Therefore, time-dependent change in fluorescence intensity by fluorescein was measured by a JASCO FP-6500 spectrofluorometer to monitor the time-course of aggregation of the R3 peptide. The excitation and emission wavelengths were 450 and 520 nm, respectively. Before measurements were taken, 1500 μ l of each buffer solution including salt, heparin, reducing agent or FKBP12, was pre-incubated at 25°C in a rectangular optical cell settled in a Peltier thermostatted cell holder with a magnetic stirrer. Aggregation of the R3 peptide was initiated by diluting 1.5 μ l of 5 mM (or 15 μ l of 0.5 mM) of the R3 peptide dissolved in 100% dimethyl sulfoxide (DMSO) in the optical cell. Fluorescence intensity was recorded with time intervals from 5 min to 4–60 h after mixing the peptide. On the other hand, we measured time-dependent change in fluorescence intensity by TAMRA to monitor time-course of aggregation of the R4 peptide as a control experiment. The excitation and emission wavelengths were 500 and 575 nm, respectively. The other experimental conditions and procedures for the R4 peptide were the same as those for the R3 peptide.

Fluorescence depolarization measurements

The fluorescence depolarization of fluorescein attached to the R3 peptide was measured by the Peltier thermostatted depolarization accessory settled on JASCO FP-6500 spectrofluorometer to investigate the interaction between the R3 peptide and FKBP12 (Weber, 1953; Lakowicz, 1983). The excitation and emission wavelengths were 450 and 520 nm, respectively. Before measurements, 1500 μ l of each buffer solution including appropriate amount of FKBP12 was pre-incubated at 25°C in a rectangular optical cell settled in the Peltier thermostatted cell holder with a magnetic stirrer. Then, 3 μ l of 0.5 mM of the R3 peptide solved in 100% DMSO was diluted in the solution. The final concentration of the peptide was set to 1 μ M, because aggregation of the peptide was not detected at this concentration. Fluorescence depolarization was measured at least 20 times for each condition, and then averaged. These measurements gave apparent dissociation constants (K_d) averaged for both of the *cis*- and *trans*-isomers.




Fig. 2. Aggregation of the R3 and R4 peptides under various conditions. Aggregation of the R3 and R4 peptides was monitored in 50 mM sodium phosphate buffer at 25°C with the relative fluorescence of fluorescein and TAMRA attached to the N-terminal amide group of the peptides, respectively. The reaction was started by diluting a 5-mM stock solution of the peptides 1000 times. The other conditions are described in each panel. (a) The aggregation of 5 μ M of the R3 peptide at pH 8.0 in the absence (empty circle) and presence (empty square) of 60 μ g/mL heparin. (b) The aggregation of the R4 peptide in the absence of heparin. (c) The aggregation of 1 μ M (empty circle), 5 μ M (empty square) and 10 μ M (empty rhombus) of the R3 peptide at pH 8.0 in the presence of 10 mM tris-(2-carboxyethyl)-phosphine hydrochloride (TCEP). (d) The aggregation of 5 μ M of the R3 peptide at pH 8.0 in the absence (empty circle) and presence (empty square) of 10 mM TCEP. (e) The aggregation of 5 μ M of the R3 peptide at pH 8.0 in the presence of 10 mM TCEP, and in 0 (empty circle), 100 (empty square) or 400 (empty rhombus) mM sodium chloride. (f) The aggregation of 5 μ M of the R3 peptide in the presence of 10 mM TCEP, and at pH 4.5 (empty circle), 5.9 (empty square), 6.9 (empty rhombus), 8.0 (empty triangle) or 9.4 (multiplication sign). The aggregation of 5 μ M of the R3 peptide at pH 8.0 in the presence of 10 mM TCEP was redundantly plotted in the panels (c), (d), (e) and (f) as a control data. The curve fitting was performed by applying a Stineman interpolating function to the data on KaleidaGraph (Hukinks).

Dynamic light scattering measurement

Aggregation of the R3 and R4 peptides were directly monitored at 25°C by dynamic light scattering method using Marvern Zetasizer μ V. During aggregation measurement, we collected 4 μ l of the reaction mixture at hourly intervals and measured ingredient size in the mixture by a laser beam of 830 nm at an angle of 90°.

Numerical analysis

Numerical analyses were performed using the Mathematica 9.0 software package (Wolfram Res.).

Results

Characterization of the R3 peptide's aggregation

To characterize aggregation of the R3 region of tau protein, we chemically synthesized the R3 peptide, the N-terminal valine of which was labeled with fluorescein (Fig. 1), and investigated its aggregation under various conditions by change in the fluorescence intensity of fluorescein. Aggregation of tau

protein and peptides has been conventionally monitored with thioflavin-S (ThS), which quantitatively associates with their aggregated forms. However, it was recently revealed that ThS itself increased the amount of aggregation of tau protein (Carlson *et al.*, 2007; Perez *et al.*, 2007). Thus, we directly labeled the tau peptide with fluorescein to monitor its aggregation in order to exclude ThS-induced artifacts.

Inducer. Polyanionic compounds, such as heparin, are well known as *in vitro* inducers for aggregation of the R3 peptide, as well as the tau protein, although the physiological inducer for NFT is not known (Carlson *et al.*, 2007). Initially, we determined whether or not heparin had a similar effect on aggregation of the labeled R3 peptide, because no experimental data have been reported for the labeled R3 peptide (Fig. 2a). As reported for the non-labeled peptides (Mizushima *et al.*, 2006), 5 μ M of the labeled R3 peptide rapidly aggregated in the presence of 60 μ g/ml of heparin, and then its aggregates gradually grew into larger particles. We also found that the peptide aggregated at this concentration even in the absence of heparin (Fig. 2a). The aggregation in the absence of heparin,

however, grew much slower than that in the presence of heparin. The sizes of the aggregated particles were measured by the dynamic light scattering method; after 20 min, the aggregations grew into large particles with mean hydrodynamic radiuses of 206.8 ± 130.6 and 16.30 ± 8.97 nm in the presence and absence of heparin, respectively. These aggregations were still soluble in the aqueous solution at that time, but precipitated within 60 h. In contrast, the labeled R4 peptide did not aggregate under the same condition (Fig. 2b), as reported by Mizushima *et al.* (2006). These results indicate that the R3 peptide intrinsically has a high propensity to aggregate. Heparin was not necessary for the R3 peptide to aggregate, but it enhanced aggregation of the R3 peptide.

Saturation point. What is the minimum concentration (saturation point) for the R3 peptide to aggregate? In general, proteins have higher aggregation propensities at lower saturation points. Is this general property true for the R3 peptide? To answer this question, we investigated aggregation of the R3 peptide at three different concentrations, 1, 5 and 10 μ M, to elucidate its concentration-dependence in aggregation, in the absence of any inducer. Figure 2c shows that 5 and 10 μ M of the peptide formed aggregates, whereas 1 μ M of the peptide did not. These results indicate that the saturation point of the R3 peptide is between 1 and 5 μ M in the absence of heparin. This value is similar to the saturation point for the intact tau protein observed in the presence of heparin (Carlson *et al.*, 2007). This, however, seems quite high in contrast with the α -amyloid (1–40) peptide, which aggregates at 40 nM under a specific condition (Ding *et al.*, 2012). Thus, the tau protein may be rather soluble among proteins forming amyloid-like fibers.

Oxidation. The tau protein isoforms have, at most, two cysteine residues. For example, the N2R4 isoform (441 amino acid residues) contains Cys291 and Cys322. Both cysteine residues are located in the MBD, Cys291 in the R2 region, and Cys322 in the R3 region. These cysteine residues formed intramolecular and intermolecular disulfide bonds and accelerated the aggregation of tau peptides (Sugino *et al.*, 2009). In the present study, only one cysteine residue, Cys322 (Cys17 in the R3 peptide's sequence), was included in the R3 peptide, suggesting that it was able to dimerize the peptide under oxidative conditions. Thus, we investigated how the oxidation of Cys17 affected the aggregation of the R3 peptide. Figure 2d shows that the R3 peptide aggregated much faster under the oxidative condition than under the reductive condition, suggesting that dimerization of the R3 peptide accelerates the aggregation. According to Sugino *et al.* (2009), two types of tau peptides, 4RMDB (R1–R2–R3–R4) and 3RMDB (R1–R3–R4), formed homodimers, with an intramolecular and intermolecular disulfide bond, respectively. After dimerization, the peptides assemble into large aggregations, depending on their sequences. The R3 peptide also aggregated under the oxidative condition, and the aggregation rate was almost the same as that of the rate of 3RMDB. Thus, the mechanism of aggregation of the R3 peptide was expected to be the same as that of 3RMDB, although they did not specifically mention it (Sugino *et al.*, 2009). The disulfide bonds, however, were not essential for the aggregation of tau peptides, including R3, 3RMDB and 4RMDB. These tau peptides aggregated, even under the reductive condition (Fig. 2d) (Sugino *et al.*, 2009), suggesting that

the aggregation mechanism under the reductive condition was different from the mechanism under the oxidative condition.

Salt effect. As shown above, heparin accelerated aggregation of the R3 peptide (Fig. 2a), suggesting that the aggregation of the peptide was driven mainly by hydrophilic interactions. Here, we measured the aggregation of the R3 peptide under various salt concentrations in the presence of the reductant to elucidate the charge effect on the aggregation. Figure 2e shows that the aggregation of the R3 peptide decreased when the salt concentration increased. The R3 peptide did not aggregate in the presence of 400 mM of sodium chloride. This result also indicated that the hydrophilic interactions affect the aggregation of the R3 peptide considerably.

pH dependency. We next investigated the type of hydrophilic amino acid residues responsible for aggregation of the R3 peptide. The R3 peptide includes eight hydrophilic residues, one aspartic acid residue, two histidine residues, four lysine residues and one tyrosine residue. Thus, we measured the aggregation of the R3 peptide at five different pHs, 4.5, 5.9, 6.9, 8.0 and 9.4, in the presence of reductant. The electrostatic interaction of the R3 peptide almost vanished at pH 9.4, because the isoelectric point of the R3 peptide is theoretically 9.98. This suggests that the hydrophobic effects were greatest at pH 9.4. In contrast, lower the pH becomes, more positive the net charge of the R3 peptide becomes. This suggests that the hydrophilic effects become the largest at pH 5.9. At the mid-range pHs, both the hydrophilic and hydrophobic effects were medium, but distribution of the local charge of the R3 peptide was dependent on the pH. We found that aggregation of the R3 peptide was at the minimum and maximum levels at pH 6.9 and 8.0, respectively (Fig. 2f), suggesting that the distribution of the local charge was more important for aggregation of the R3 peptide than the net charge of the peptide. Furthermore, the transition to aggregation of the R3 peptide occurred between pH 6.9 and 8.0, suggesting that distribution of the local charge of the peptide changed between pH 6.9 and 8.0. One of the candidate mechanisms for changing the charge is deprotonation of the histidine residue. The R3 peptide contains two histidine residues, His24 and His25. The local positive charge around the histidine residues might be related to aggregation of the R3 peptide.

In summary, the R3 peptide aggregated even in the absence of inducer, and the aggregation was driven by hydrophilic interaction. The deprotonation of histidine seemed to affect aggregation of the peptide.

Aggregation inhibition by FKBP12

The R3 peptide contains two proline residues, Pro7 and Pro27. The proline residues are not the target for Pin1 but are the targets for FKBP12, because Lys6 and Lys26 precede the proline residues (Yaffe, 1997). In order to elucidate the aggregation inhibitory activity of FKBP12, we measured aggregation of the R3 peptide in various concentrations of FKBP12 by change of fluorescence intensity of fluorescein. Figure 3a shows that R3 peptide aggregation decreased when the concentration of FKBP12 increased. No peptide aggregation was detected in the presence of 20 μ M of FKBP12. This result clearly indicated that FKBP12 prevents the R3 peptide from aggregating. We calculated that 50% inhibitory concentration (IC_{50}) of FKBP12 under the conditions was 3 μ M (Fig. 3b).






Fig. 3. (a) Aggregation of the R3 peptides in the presence of FKBP12. The aggregation of 5 μM of the R3 peptide was monitored in the presence of 0 (empty circle), 2.5 (empty square), 10 (empty rhombus) or 20 (empty triangle) μM FKBP12 at pH 8.0 and 25°C with the relative fluorescence of fluorescein. The reaction started by diluting 0.5-mM stock solution of the peptide 100 times. The reaction mixture also contained 50 mM sodium phosphate and 10 mM TCEP. Curve fitting was performed by applying a Stineman interpolating function to the data on KaleidaGraph (Hukinks). (b) The normalized amount of aggregation in the presence of FKBP12. The normalized amount of aggregation was calculated by dividing the decrease in fluorescence during the first 180 min by the decrease in the absence of FKBP12. Curve fitting was based on the two-state transition theory. The 50% inhibitory concentration (IC₅₀) of FKBP12 was calculated at 3 μM on the basis of this graph.



Scheme 1. The inhibitory mechanism of R3 peptide aggregation by simple binding of FKBP12. In this scheme, only the *cis*-isomer of the R3 peptide can aggregate, to which FKBP12 specifically and tightly binds. FKBP12 catalyzes isomerization of Xaa-Pro motifs of the R3 peptide only in the monomeric state. Association between FKBP12 and the *cis*-isomer is much faster than self-association of the *cis*-isomer because the concentration of the *cis*-isomer is very low. Therefore, FKBP12 intercepts the *cis*-isomer during its aggregation.

There are two possible explanations for the mechanism of how FKBP12 prevents the R3 peptide from aggregating (Schemes 1 and 2). One is that FKBP12 sequesters the R3 peptide: (i) FKBP12 tightly binds to the R3 peptide, (ii) the effective concentration of the R3 peptide decreases to less than its saturation point and (iii) FKBP12 also interacts with oligomers of the R3 peptide at the early stage of aggregation,



Scheme 2. The inhibitory mechanism of R3 peptide aggregation by PPIase activity of FKBP12. In this scheme, only the *cis*-isomer of the R3 peptide can aggregate, and FKBP12 does not tightly bind to either isomer. FKBP12 catalyzes isomerization of Xaa-Pro motifs of the R3 peptide in both the monomeric and aggregative state. Once the *cis*-isomer is converted into the *trans*-isomer in the aggregative state, the *trans*-isomer is quickly released from the aggregation because the *trans*-isomer cannot aggregate.

leading to dissociation of the peptide (Scheme 1). The other possible explanation is that FKBP12 catalyzes isomerization from the higher aggregation-prone isomer to the lower one: (i) FKBP12 binds more tightly to the higher aggregation-prone isomer of the R3 peptide than to the lower one, and (ii) FKBP12 catalyzes isomerization from the higher aggregation-prone isomer to the lower one as well as Pin1 and (iii) FKBP12 also functions for oligomers of the R3 peptide at the early stage of aggregation, leading to dissociation of the peptide (Scheme 2). Both schemes have the association of FKBP12 with the R3 peptide in common. However, they are




Fig. 4. (a) The positions of mutations on the tertiary structure of FKBP12. The two residues are drawn with a stick model. (b) Aggregation of 5 μM of the R3 peptides in the presence of 5 μM wild-type FKBP12 (empty circle), 5 μM FKBP12/Tyr82Lys (empty square) and 5 μM FKBP12/Val55Arg (empty rhombus), and in the absence of FKBP12 (empty triangle). The other conditions are the same as described in Fig. 3. Curve fitting was performed by applying a Stineman interpolating function to the data on KaleidaGraph (Hukinks). (c) Fluorescence depolarization of fluorescein attached to the R3 peptide for titration of wild-type FKBP12 (empty circle), FKBP12/Tyr82Lys (empty square) and FKBP12/Val55Arg (filled square). The concentration of R3 peptide needed to prevent aggregation was 1 μM . Curve fitting was based on the two-state transition theory. The dissociation constant (K_d) for wild-type FKBP12 was calculated at 271 μM . The K_d values for the mutant proteins could not be determined because of the very weak interaction between the peptide and the mutant proteins.

different in the catalytic reaction of FKBP12. FKBP12 only sequesters the peptide in the former scheme, while it catalyzes the isomerization of Xaa-Pro bonds of the peptide in the latter scheme.

To determine which scheme is applicable to the function of FKBP12, we introduced two types of mutations into FKBP12; one mutation increased the PPIase activity, and the other mutation decreased the activity. A Val55 \rightarrow Arg mutation (FKBP12/Val55Arg) increased PPIase activity by a factor of 11, while a Tyr82 \rightarrow Lys mutation (FKBP12/Tyr82Lys) decreased the activity by a factor of 7 (Fig. 4a) (Ikura and Ito, 2007). In order to elucidate the effect of PPIase activity, we measured the aggregation of 5 μM of the R3 peptide in the presence of 5 μM of each of these mutant proteins by change in fluorescence intensity of fluorescein. Moreover, in order to elucidate how the mutations affect the association between FKBP12 and the R3 peptide, we measured the affinities of the proteins to the R3 peptide by the fluorescence depolarization method. In this affinity study, concentration of the R3 peptide was decreased to 1 μM because the R3 peptide did not aggregate at this concentration (Fig. 2c). As the results indicated, the R3 peptide did not aggregate in the presence of FKBP12/Val55Arg, while FKBP12/Tyr82Lys did not inhibit the aggregation (Fig. 4b). In the presence of FKBP12/Val55Arg, the R3 peptide aggregated transiently at first, then gradually dissociated and finally, the peptide was completely restored from the aggregation. The apparent dissociation constant (K_d) for wild-type FKBP12 was calculated as 271 μM , whereas the K_d s for each of the two mutants was much $>271 \mu\text{M}$ (Fig. 4c). These affinities were too low for K_d calculation by the fluorescence depolarization method. These results indicated that higher the PPIase activity of FKBP12, higher its aggregation inhibitory activity. The results also indicated that the aggregation inhibitory activity of FKBP12 was independent of the affinity between FKBP12 and the R3 peptide. Therefore, the aggregation inhibitory activity of FKBP12 depended only on the PPIase activity of FKBP12, as represented by Scheme 2.




Fig. 5. Theoretical analysis of the aggregation of the R3 peptide in the presence of FKBP12. Each curve was calculated by numerically solving the differential equations derived from Scheme 2. The solid and dotted lines indicate the highest and lowest concentrations of FKBP12, respectively. Two dashed lines represent the mid-level concentration of FKBP12. This figure reflects Fig. 3 as well, indicating that Scheme 2 is a good descriptor of the function of FKBP12.

Discussions

Mechanism of FKBP12 inhibition of R3 peptide aggregation

As shown in Fig. 3a, 20 μM of FKBP12 completely inhibited aggregation of the R3 peptide. Mutational studies on FKBP12 showed that the aggregation inhibitory activity of FKBP12 is attributable mainly to its PPIase activity (Fig. 4b and c). Furthermore, FKBP12 not only acted on the R3 peptide in the monomeric state but also in the aggregative state (Fig. 4a). This restoration of the R3 peptide from aggregate to monomer suggests that the R3 peptide aggregation formed at the early stage does not strongly resist the attack by FKBP12. These features of the aggregation of the R3 peptide in the presence of FKBP12 are well described in Scheme 2. On the other hand, the mutational studies showed that the aggregation inhibitory mechanism of FKBP12 was inconsistent with Scheme 1, because the mutation Val55 \rightarrow Arg weakened the association

between FKBP12 and the peptide, but raised the aggregation inhibitory activity (Fig. 4b and c). Here, we theoretically examined how Scheme 2 reproduced the experimental results. In simulating the inhibition of R3 peptide aggregation by FKBP12 in Scheme 2, we simplified the reaction so that (i) only the *cis*-isomer of the Xaa-Pro motif aggregated irreversibly, (ii) FKBP12 accelerated the isomerization between *cis*- and *trans*-isomers in monomeric and aggregative states and (iii) only the *trans*-isomer in the aggregative state quickly dissociated from the aggregation. As a result, the acceleration of isomerization decreased the amount of aggregation of the R3 peptide (Fig. 5), indicating that Scheme 2 describes the experimental results, in which FKBP12 restored the R3 peptide from the aggregation. Although no structural information is available to explain the difference between the *cis*- and *trans*-isomers, we can interpret this issue on the basis of pH dependency of the aggregation (Fig. 2f). Aggregation of the R3 peptide was sensitive to the distribution of local charge. The *cis*- and *trans*-isomers are probably different from each other in the distribution of local charge. Therefore, the *cis*-isomer is much aggregative than the *trans*-isomer, as reported for the aggregation propensity of the pThr231-Pro232 motif (Nakamura *et al.*, 2012).

In 2001, von Bergen *et al.* pointed out that Pro312 was important for aggregation propensity of the R3 peptide (von Bergen *et al.*, 2001). They reported that a deletion mutant of a short R3 peptide (Val306-Lys317), which lacked only Pro312, showed a pronounced shift to β -structure and enhanced the aggregation, indicating that the aggregation propensity of the R3 peptide correlated with the β -structure content for residues around the Val306-Lys311 motif, and Pro312 in the intact sequence broke elongation of β -structure by its restricted conformation. This means that Pro312 suppresses aggregation of the R3 peptide. Although they did not investigate the isomerization of Pro312, this suppressive effect should be brought about by the *trans*-isomer because it is in majority. The *cis*-isomer might have higher β -structure content for the R3 peptide than the *trans*-isomer. Therefore, isomerization of Pro312 presumably attributes to the aggregation propensity of the R3 peptide.

In vivo function of FKBP12

FKBP12 was first discovered as the receptor for an immunosuppressor in the immune system (Harding *et al.*, 1989; Siekierka *et al.*, 1989). It was later revealed that FKBP12 had multiple functions in cells. FKBP12 interacts with signal transduction proteins such as the type-1 transforming growth factor receptor (Chen *et al.*, 1997), and with multiple intracellular calcium release channels, such as the tetrameric skeletal muscle ryanodine receptor (Gaburjakova *et al.*, 2001). FKBP12 is also abundantly expressed in the brain and accumulates in NFT (Sugata *et al.*, 2009). However, whether or not FKBP12 is concerned with the aggregation process of tau protein was still unclear. In this study, we clearly demonstrated that FKBP12 prevented the R3 peptide from aggregating *in vitro*. Although a short fragment of tau protein, the R3 region was essential for tau protein to aggregate (Perez *et al.*, 2007). Therefore, it is expected that FKBP12 prevents tau protein aggregation by interacting with the R3 region of tau protein *in vivo*, as it acts upon the R3 peptide *in vitro*. In its *in vitro* aggregation inhibitory activity, FKBP12 catalyzed the isomerization both of monomeric and aggregative states, suggesting that

such isomerization catalysis is also essential for its *in vivo* aggregation inhibitory activity.

PPIase versus NFT

At least four PPIases, Pin1, FKBP12, FKBP51 and FKBP52, are estimated to be responsible for stabilizing and destabilizing the tau protein *in vivo* (Cao and Konsolaki, 2011; Nakamura *et al.*, 2012). Pin1 interacts with the pSer/Thr-Pro motifs in the tau protein and isomerizes the higher aggregative *cis*-isomer to the low aggregative *trans*-isomer. The functions of FKBP51 and FKBP52 are related to association and dissociation between the tau protein and two types of tubulins. However, whether or not the PPIase activities of both FKBP51 and FKBP52 are concerned with the function is unknown, because they consist of several functional domains. On the other hand, this study suggested that PPIase activity of FKBP12 was essential in preventing tau protein aggregation. Thus, many PPIases and their PPIase activities regulate the tau protein. Such a feature of the tau protein might be related to one of its structural properties, in which it is intrinsically disordered (Skrabana *et al.*, 2006).

Acknowledgements

We thank Professor Nobuhiro Takahashi (Tokyo University of Agriculture and Technology) for providing the cloned gene of human FKBP12.

Funding

This work was supported by Grants-in-Aid for Scientific Research (No 22113504) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanowski, J.Q. and Lee, V.M. (1993) *Neuron*, **10**, 1089–1099. First published on 1993/06/01.
- Brion, J.P., Smith, C., Couck, A.M., Gallo, J.M. and Anderton, B.H. (1993) *J. Neurochem.*, **61**, 2071–2080. First published on 1993/12/01.
- Cao, W. and Konsolaki, M. (2011) *J. Biosci.*, **36**, 493–498. First published on 2011/07/30.
- Carlson, S.W., Branden, M., Voss, K., Sun, Q., Rankin, C.A. and Gamblin, T.C. (2007) *Biochemistry*, **46**, 8838–8849. First published on 2007/07/05. doi: 10.1021/bi700403a.
- Chambraud, B., Sardin, E., Giustiniani, J., Dounane, O., Schumacher, M., Goedert, M. and Baulieu, E.E. (2010) *Proc. Natl Acad. Sci. USA*, **107**, 2658–2663. First published on 2010/02/06. doi: 10.1073/pnas.0914957107.
- Chen, Y.G., Liu, F. and Massague, J. (1997) *EMBO J.*, **16**, 3866–3876. First published on 1997/07/01. doi: 10.1093/emboj/16.13.3866.
- Ding, H., Schauerte, J.A., Steel, D.G. and Gafni, A. (2012) *Biophys. J.*, **103**, 1500–1509. First published on 2012/10/16. doi: 10.1016/j.bpj.2012.08.051.
- Gaburjakova, M., Gaburjakova, J., Reiken, S., Huang, F., Marx, S.O., Roseblit, N. and Marks, A.R. (2001) *J. Biol. Chem.*, **276**, 16931–16935. First published on 2001/03/30. doi: 10.1074/jbc.M100856200.
- Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E. and Klug, A. (1988) *Proc. Natl Acad. Sci. USA*, **85**, 4051–4055. First published on 1988/06/01.
- Goedert, M., Jakes, R., Crowther, R.A., Six, J., Lubke, U., Vandermeeren, M., Cras, P., Trojanowski, J.Q. and Lee, V.M. (1993) *Proc. Natl Acad. Sci. USA*, **90**, 5066–5070. First published on 1993/06/01.
- Hamdane, M., Smet, C., Sambo, A.V., *et al.* (2002) *J. Mol. Neurosci.*, **19**, 275–287. First published on 2003/01/24. doi: 10.1385/JMN:19:3:275.
- Hamdane, M., Dourlen, P., Bretteville, A., *et al.* (2006) *Mol. Cell. Neurosci.*, **32**, 155–160. First published on 2006/05/16. doi: 10.1016/j.mcn.2006.03.006.
- Harding, M.W., Galat, A., Uehling, D.E. and Schreiber, S.L. (1989) *Nature*, **341**, 758–760. First published on 1989/10/26. doi: 10.1038/341758a0.
- Ikura, T. and Ito, N. (2007) *Protein Sci.*, **16**, 2618–2625. First published on 2007/11/22. doi: 10.1110/ps.073203707.
- Jinwal, U.K., Koren, J., III, Borysov, S.I., *et al.* (2010) *J. Neurosci.*, **30**, 591–599. First published on 2010/01/15. doi: 10.1523/JNEUROSCI.4815-09.2010.

- Kopke,E., Tung,Y.C., Shaikh,S., Alonso,A.C., Iqbal,K. and Grundke-Iqbal,I. (1993) *J. Biol. Chem.*, **268**, 24374–24384. First published on 1993/11/15.
- Lakowicz,J.R. (1983) *Principles of Fluorescence Spectroscopy*. Plenum Press, New York.
- Landrieu,I., Leroy,A., Smet-Nocca,C., *et al.* (2010) *Biochem. Soc. Trans.*, **38**, 1006–1011. First published on 2010/07/28, doi: 10.1042/BST0381006.
- Lindwall,G. and Cole,R.D. (1984) *J. Biol. Chem.*, **259**, 12241–12245. First published on 1984/10/10.
- Liu,F., Li,B., Tung,E.J., Grundke-Iqbal,I., Iqbal,K. and Gong,C.X. (2007) *Eur. J. Neurosci.*, **26**, 3429–3436. First published on 2007/12/07, doi: 10.1111/j.1460-9568.2007.05955.x.
- Lu,P.J., Wulf,G., Zhou,X.Z., Davies,P. and Lu,K.P. (1999) *Nature*, **399**, 784–788. First published on 1999/07/03, doi: 10.1038/21650.
- Mizushima,F., Minoura,K., Tomoo,K., Sumida,M., Taniguchi,T. and Ishida,T. (2006) *Biochem. Biophys. Res. Commun.*, **343**, 712–718. First published on 2006/03/28, doi: 10.1016/j.bbrc.2006.02.185.
- Morishima-Kawashima,M., Hasegawa,M., Takio,K., Suzuki,M., Yoshida,H., Watanabe,A., Titani,K. and Ihara,Y. (1995) *Neurobiol. Aging*, **16**, 365–371. discussion 371–380. First published on 1995/05/01.
- Nakamura,K., Greenwood,A., Binder,L., Bigio,E.H., Denial,S., Nicholson,L., Zhou,X.Z. and Lu,K.P. (2012) *Cell*, **149**, 232–244. First published on 2012/04/03, doi: 10.1016/j.cell.2012.02.016.
- Ogawa,Y., Nonaka,Y., Goto,T., *et al.* (2010) *Nat. Commun.*, **1**, 86. First published on 2010/10/29, doi: 10.1038/ncomms1090.
- Perez,M., Arrasate,M., Montejo De Garcini,E., Munoz,V. and Avila,J. (2001) *Biochemistry*, **40**, 5983–5991. First published on 2001/05/16.
- Perez,M., Santa-Maria,I., Tortosa,E., Cuadros,R., Del Valle,M., Hernandez,F., Moreno,F.J. and Avila,J. (2007) *J. Neurochem.*, **103**, 1447–1460. First published on 2007/08/08, doi: 10.1111/j.1471-4159.2007.04834.x.
- Ramakrishnan,P., Dickson,D.W. and Davies,P. (2003) *Neurobiol. Dis.*, **14**, 251–264. First published on 2003/10/24.
- Siekierka,J.J., Hung,S.H., Poe,M., Lin,C.S. and Sigal,N.H. (1989) *Nature*, **341**, 755–757. First published on 1989/10/26, doi: 10.1038/341755a0.
- Skrabana,R., Skrabanova,M., Csokova,N., Sevcik,J. and Novak,M. (2006) *Bratisl. Lek. Listy*, **107**, 354–358. First published on 2007/02/01.
- Smet,C., Sambo,A.V., Wieruszeski,J.M., Leroy,A., Landrieu,I., Buee,L. and Lippens,G. (2004) *Biochemistry*, **43**, 2032–2040. First published on 2004/02/18, doi: 10.1021/bi035479x.
- Sugata,H., Matsuo,K., Nakagawa,T., Takahashi,M., Mukai,H., Ono,Y., Maeda,K., Akiyama,H. and Kawamata,T. (2009) *Neurosci. Lett.*, **459**, 96–99. First published on 2009/05/06, doi: 10.1016/j.neulet.2009.04.062.
- Sugino,E., Nishiura,C., Minoura,K., In,Y., Sumida,M., Taniguchi,T., Tomoo,K. and Ishida,T. (2009) *Biochem. Biophys. Res. Commun.*, **385**, 236–240. First published on 2009/05/20, doi: 10.1016/j.bbrc.2009.05.047.
- von Bergen,M., Barghorn,S., Li,L., Marx,A., Biernat,J., Mandelkow,E.M. and Mandelkow,E. (2001) *J. Biol. Chem.*, **276**, 48165–48174. First published on 2001/10/19, doi: 10.1074/jbc.M105196200.
- Weber,G. (1953) *Adv. Protein Chem.*, **8**, 415–459. First published on 1953/01/01.
- Weingarten,M.D., Lockwood,A.H., Hwo,S.Y. and Kirschner,M.W. (1975) *Proc. Natl Acad. Sci. USA*, **72**, 1858–1862. First published on 1975/05/01.
- Yaffe,M.B. (1997) *Science*, **278**, 1957–1960. First published on, doi: 10.1126/science.278.5345.1957.
- Yoshida,H. and Ihara,Y. (1993) *J. Neurochem.*, **61**, 1183–1186. First published on 1993/09/01.
- Zhou,X.Z., Kops,O., Werner,A., *et al.* (2000) *Mol. Cell*, **6**, 873–883. First published on 2000/11/25.
- Zhou,L.X., Zeng,Z.Y., Du,J.T., Zhao,Y.F. and Li,Y.M. (2006) *Biochem. Biophys. Res. Commun.*, **348**, 637–642. First published on 2006/08/08, doi: 10.1016/j.bbrc.2006.07.099.

The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA

Haruyuki Fujita¹, Toshio Kitawaki¹, Takayuki Sato¹, Takahiro Maeda², Shimeru Kamihira³, Akifumi Takaori-Kondo¹ and Norimitsu Kadowaki^{1,4}

¹ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

² Department of Island and Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

³ Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

⁴ Japan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST), Tokyo, Japan

Plasmacytoid dendritic cells (pDCs) produce a vast amount of interferon (IFN)- α in response to nucleic acids from viruses and damaged self-cells through Toll-like receptor (TLR)7 and TLR9. Pharmaceutical agents that suppress IFN- α production by pDCs are instrumental in elucidating the mechanisms behind IFN- α production, and in developing novel therapies for inflammatory disorders that involve pDCs. Here, we show that a tyrosine kinase inhibitor for chronic myeloid leukemia with multiple targets, dasatinib, strongly suppresses production of IFN- α and proinflammatory cytokines by human pDCs stimulated with multimeric CpG oligodeoxynucleotides (CpG-A) without reducing viability. In contrast, other tyrosine kinase inhibitors, imatinib, and nilotinib, did not suppress the cytokine production at clinically relevant concentrations. Inhibitors of SRC family kinases (SFKs), which are prominent targets of dasatinib, also suppressed the cytokine production. Notably, however, dasatinib, but not SFK inhibitors, abrogated prolonged localization of CpG-A in early endosomes, which is a critical step for pDCs to produce a large amount of IFN- α . This study suggests that dasatinib suppresses IFN- α production by pDCs by inhibiting SFK-dependent pathways and SFK-independent endosomal retention of CpG DNA. Kinases controlling the distinctive endosomal trafficking in pDCs may be exploited as targets to develop novel therapies for pDC-related inflammatory disorders.

Keywords: Dasatinib · Interferon · Plasmacytoid dendritic cells (pDCs) · TLR9



Additional supporting information may be found in the online version of this article at the publisher's web-site

Introduction

Plasmacytoid DCs (pDCs) are a distinctive immune cell type that produces a vast amount of IFN- α in response to virus-derived CpG DNA or ssRNA through TLR9 or TLR7, respectively [1], thus

Correspondence: Dr. Norimitsu Kadowaki
e-mail: kadowaki@kuhp.kyoto-u.ac.jp